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Abstract
Chemical homeostasis is a baseline requirement for any cell to survive. ATP-binding cassette
(ABC) transporters play a vital role in homeostasis by importing nutrients and exporting toxins against their
concentration gradients by utilizing the energy of ATP hydrolysis. Malfunctioning ABC transporters cause
a variety of health problems, including cystic fibrosis, Stargardt’s disease (vision loss), and the development
of drug-resistant tumors. An important step in solving these medical issues is to first understand the
structure and mechanism of ABC transporters. Various studies have made great strides in depicting the
structure and details of different ABC transporters and their mechanisms, however, many of these details
were discovered with transporters in highly artificial environments using X-ray crystallography. This
project aims to further understand the mechanism of the E. coli methionine importer MetNI using functional
studies.
A fluorescence anisotropy assay was developed as a functional study that would assess the
dissociation constant between MetNI and its periplasmic binding protein MetQ. ATP-binding by MetNI
was found to be a prerequisite for MetNI-Q complex formation. MetNI saw a slightly higher affinity for
apo MetQ (Kd = 281 nM ± 36 nM) than L-Met bound MetQ (527 nM ± 107 nM). These similar binding
affinities support the hypothesis that MetNI follows two different mechanisms originally proposed by
Nguyen et. al.; one for the preferred L-Met substrate, and one for L-Met derivatives in situations of L-Met
scarcity. Preliminary trials investigating the dissociation constant between the MetNI C2 domains and LMet found a Kd dissociation constant between the MetNI C2 domains and L-Met of 484 nM. Moving
forward, the ATP requirements for MetNI-Q complex formation will be investigated using MetNI
transporters with nucleotide binding domain chimeras.

x

Chapter 1: Introduction

1.1: The Lipid Bilayer and Membrane Proteins
A crucial requirement for cell survival is maintaining an optimal internal chemical environment.
The cell must consistently maintain homeostasis, which includes variables such as pH, ion and solute
concentration, and redox state. To maintain the proper internal environment, the cell creates a semipermeable membrane to separate its intracellular compartment from the extracellular space. The membrane
consists of a lipid bilayer, arranged with hydrophobic tails facing inward and hydrophilic heads facing
outward. The bilayer forms a flexible yet strong barrier, approximately 3-4 nm thick and with remarkable
fluidity in the lateral plane.1
While small, nonpolar molecules such as oxygen and carbon dioxide gas move unassisted through
the membrane, other molecules that are large or polar are unable to traverse the barrier by simple diffusion.
To assist with molecular transport, cellular membranes contain a variety of integral membrane proteins that
provide permeation pathways for the movement of specific substrates through the lipid bilayer. In general,
integral membrane proteins are involved in a variety of tasks including intercellular adhesion, signal
transduction pathways, enzymatic activity, and cell-to-cell recognition; however, substrate transport is the
most vital activity in maintaining chemical
homeostasis.2 This project focuses on membrane
proteins that drive substrate transport.
Approximately 10% of the E. coli genome
plays a role in transport processes, suggesting a
similarly significant ratio of genomic data tied to
transport in all cell species.3 There are two main
types of integral membrane proteins that support
transport: passive and active transporters. Passive
transporters, also referred to as channels, facilitate
Figure 1-1: Passive and active transporters. Passive
transporters are essential for facilitated diffusion while active
transporters utilize ATP hydrolysis to import substrates
against their concentration gradient. Image taken directly
from (4).

movement along concentration gradients by
forming highly selective, regulated pathways
through the membrane (Fig. 1-1).4 In many cases,

channels can be activated or “gated” in response to stimuli, including certain ligands, changes in membrane
potential, and physical membrane distortion. In contrast, active transporters require energy to move
substrates against a concentration gradient. These intermembrane “pumps” utilize the energy stored in
multiple forms, including photons, a secondary chemical gradient, or more commonly, ATP. The focus of
this thesis falls under the branch of ATP-driven transporters.
1

1.2: ATP-Driven Transport
At least 10% of the ATP requirements of bacterial and human cells are dedicated to substrate
transport.2 There are four types of ATP-driven pumps: P-class, V-class, F-class, and ATP-binding cassette
(ABC) transporters (Fig. 1-1).4 Each type of transporter is highly selective for particular substrates, and
many of them are regulated in response to physiological needs and environmental availability. The
divergence into four different types allows these ATP-driven pumps to perform a multitude of functions in
various locations within the cell. ATP-driven pumps play diverse biological roles, including importing and
exporting a variety of substrates, acidifying lysosomes that break down harmful antigens, generating the
intracellular and extracellular ion concentrations crucial to neuron communication, and synthesizing ATP
in the mitochondria.
P-class pumps, often referred to as P-type ATPases, are responsible for the transport of many types
of ions (Na+, K+, Ca2+, H+) and phospholipid molecules. A prominent example of a P-type ATPase is the
sodium-potassium pump, which maintains the electrochemical gradient necessary for transmission of nerve
impulses. This class also includes several heavy metal pumps, which regulate metal homeostasis as well as
metal resistance in several organisms.5 With P-class pumps, the transporter itself is covalently modified via
ATP phosphorylation. When substrate is bound to the transporter, phosphorylation at a conserved aspartate
residue triggers a conformational change. This structural rearrangement translocates the substrate from one
side of the membrane to the other.4
V-class and F-class ATPases are both responsible for proton transport and have similar structures.
The most recognized example of the F-class ATPase is ATP synthase. In this transporter, energy is captured
from the flow of H+ down its concentration gradient via a rotary structure. This rotary structure converts
kinetic rotational energy into potential energy in the form of ATP. Conformational changes in the
transporter bring ADP and inorganic phosphate together in the proper arrangement to form ATP. These two
classes of transporter are also responsible for pumping H+ ions from the cytosol into lysosomes, acidifying
and breaking down any contaminants the lysosome may hold.
Lastly, ABC transporters transport a wide variety of substrates, ranging from individual ions to
large siderophore compounds. Each transporter serves its unique purpose and is highly specific for its
substrate or set of substrates. These transporters exist in all kingdoms of life, and the ABC superfamily is
larger and more diverse than any other type of ATP-driven pumps.6 Hundreds of transporters have been
found in organisms ranging from prokaryotes to humans [for a recent review, see (6)]. ABC transporters
are divided into two main functional categories: importers and exporters. Importers, which are only found
in prokaryotes, facilitate the uptake of molecules such as carbohydrates, amino acids, and vitamins against
their concentration gradients. Exporters use the energy of ATP binding and hydrolysis to transfer
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metabolites, toxins, and peptides out of the cell, likewise against their concentration gradients. Unlike the
P-type pumps, not a single ABC transporter has been discovered that is both an importer and an exporter.6

1.3: ABC Transporter Malfunctions and Their Consequences
A total of 49 ABC transporters have been identified in the human body and several of these and
several of these transporters are linked to various health conditions.7 Mutations in ABC transporters lead
to diseases such as cystic fibrosis, Stargardt’s disease, and drug-resistant tumors8,9,10. Cystic fibrosis is
caused by a malfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) transporter.
The CFTR transporter is present in epithelial cells lining the lungs and is the only known ABC transporter
that serves as an ion channel. Interestingly, the ATPase functionality has been lost for CFTR, and thus it is
sometimes referred to as a “broken” ABC transporter. The channel allows for proper anion flow between
extracellular fluid and epithelial cells, which in turn mediates the amount of liquid that epithelial cells
absorb. This process ensures the proper viscosity of mucus in the lungs. A mutation in the CFTR transporter
leads to a decrease in anion flow, triggering epithelial cells to absorb water, but not anions, thereby
thickening mucus in the lungs and decreasing its fluidity. Ultimately, this malfunctioning transporter results
in a buildup of viscous mucus in the lungs that increases the risk of life-threatening bacterial infections.8
A mutation of ABC transporter ABCA4 can lead to Stargardt’s disease, for which the main
pathology is vision loss. The ABCA4 transporter exports harmful by-products of the visual cycle performed
by cells within the retina. When the transporter malfunctions, these toxic by-products accumulate in the
retina, ultimately causing cell death and a gradual loss in central vision.9
Some ABC exporters are promiscuous in terms
of their substrate specificity. These exporters, including
P-gp, MRP, and BCRP, transport large hydrophobic
compounds, such as chemotherapeutics, in tumor
cells.10 This adaptation allows cancers cells to expel
foreign, toxic molecules before they can accumulate at
an effective intracellular concentration, a phenomenon
termed “multi-drug resistance.” This deleterious
adaptation works against a variety of anti-cancer drugs,
making cancerous tumors even more difficult to treat
(Fig. 1-2).11 If medicine is to ever cure the diseases
caused

by

malfunctioning

ABC

transporters, Figure 1-2: A model of a mutated ABC exporter

removing anticancer drugs from a tumor cell. Image

researchers must first completely understand the inspired by (10).
structure and mechanisms of action of ABC transporters.
3

1.4: Structure and Function of ABC Transporter Components
1.4.1: General Structure
ABC transporters consist of a minimum of four domains: two
transmembrane domains (TMDs) embedded in the lipid bilayer, and
two nucleotide binding domains (NBDs) located on the cytoplasmic
side of the membrane where ATP is available for binding and
hydrolysis (Fig. 1-3).6 Coupling helices connect the TMDs to the
NBDs and are largely responsible for linking the conformational
changes between each subunit.

Figure 1-3: General structure of an
ABC transporter. For every transporter
there are two NBDs, two TMDs, and
coupling helices at each NBD-TMD
junction. Image taken directly from (6).

1.4.2: Nucleotide Binding Domains
The nucleotide binding domains (NBDs) are highly

conserved regions of the transporter, meaning that the nucleic acid sequence in this region is nearly identical
across the entire ABC transporter family. The NBD is responsible for ATP binding and hydrolysis. The
two NBDs of an ABC transporter come together to form two ATP-binding pockets at the interface of the
subunits (Fig. 1-4). Each NBD can be divided into two constituent domains: the RecA domain and the
alpha-helical domain. ATP-binding sites are formed when the RecA domain of one NBD and the alphahelical domain of the other NBD come together. Overall, this forms two ATP-binding sites in the NBD
region of one transporter.
The RecA domain contains universally conserved regions
such as the Walker A and B motifs, and H-motif. The Walker A
motif, also known as the P-loop, binds the 𝛼 and 𝛽-phosphates of
ATP. The Walker B motif and the H-motif are recognized for their
role in initiating ATP hydrolysis (Fig. 1-5). The glutamate side
chain from the Walker B motif, and the histidine side chain from
the H-motif are candidates for the general base that polarizes a
Figure 1-4: A simplified structure of

nearby water molecule to enable nucleophilic attack, leading to the nucleotide binding domain (NBD).
hydrolysis of ATP.12 This Walker B motif also anchors the Mg2+ See text for description.
that coordinates and positions the ATP molecule.13

The alpha-helical domain is more diverse between ABC transporters; however, it contains three
conserved regions: the ABC signature motif, the D-loop, and the Q-loop. The ABC signature motif
(LSGGQ) plays a crucial role in ATP binding by forming hydrogen bonds to the 𝛾-phosphate of the ATP
molecule (Fig 1-5). The D-loop consists of the amino acid sequence EATSALD. The N-terminal glutamate
(E) engages one active site while the C-terminal aspartate (D) engages the P-loop of the opposite active
4

site. With a connection to both active sites, researchers believe the D-loops play a crucial role in the
communication between active sites.14 The third conserved region is the Q-loop, which interacts with the
ATP binding site and plays a large role in coupling ATP hydrolysis with the movement of the
transmembrane domain. The Q-loop is highly flexible and can adopt different structural conformations in
response to ATP binding and hydrolysis. The conformation of the Q-loop transmits information about the
nucleotide state of the NBDs to the TMDs.15

A

B

Figure 1-5: Location of various conserved regions of the NBD. (a) Location of the Walker A, Walker B, Q-loop, ABC signature
motif, and H-motif in the NBD’s primary structure. (b) Location of the Walker A (labeled as P), Walker B (B), H-motif (H), Qloop (Q), and ABC signature motif (ABC) in a crystal structure of a vitamin B12 (BtuCD) transporter. Images taken directly from
(6).

1.4.3: Transmembrane Domains
The transmembrane domains (TMDs) of the ABC transporter constitute the portion of the
transporter that is embedded in the lipid bilayer and forms the permeation pathway for substrate transport.
Alpha helices traverse the membrane several times, varying from 5 to 10 helices per TMD, for a total of
10-20 helices for a complete transporter. There is considerable variation in the structure of the TMDs across
different ABC transporters, which reflects the diversity in substrate specificity. Variability in the
architecture of the transmembrane helices is the basis for the classification system of ABC transporters (see
Section 1.5 for a more detailed description).
A common feature of all TMDs is the interaction with the NBDs via “coupling helices.” These
relatively flexible structures contain a universal three amino acid motif, EAA. The helices form noncovalent interactions with the Q-loop of the NBDs and can thus reposition in response to structural changes
in the NBDs. In effect, the nucleotide state and conformation of the TMDs are linked, or coupled, thereby
capturing the energy in ATP to drive substrate transport.16
5

1.4.4: Substrate Binding Protein
A crucial component of ABC importers is their cognate substrate binding protein (SBP). The
location of an SBP differs depending on the cell type in which it resides. SBPs in Gram-negative bacteria
are untethered in the periplasmic space and bind to the transporter via non-covalent interactions. Substrate
binding proteins in Gram-positive bacteria are either anchored to the lipid bilayer adjacent to the ABC
transporter or are fused to the TMDs of the transporter itself.17 SBPs have a bilobal architecture, and the
two lobes are maneuverable to change conformation depending on substrate conditions. The lobes rotate
on a hinge, coming together when substrate binds in-between them separating once the substrate has
dissociated.18 This conformational change is often referred to as the “Venus flytrap mechanism” for its
similarity to the opening and closing of the carnivorous plant’s leaf.19 (Interestingly, integral membrane
proteins related to ABC transporters translate the physical presence of an insect to an action potential that
drives the closure of the leaf.)
The highly specific SBPs are thought to sequester substrates in the periplasm and deliver them to
the membrane-embedded transporter (see Section 1.6 for a more detailed description). While this model is
the most intuitive, work by some groups suggests that SBPs for certain transporters may play different roles.
For example, work by the Duong group demonstrated that the SBP is less likely to complex with the maltose
transporter when substrate concentrations are high.20 This reduction in complex formation was proposed to
serve as a method for limiting ATP hydrolysis when the cell has access to a sufficient amount of maltose
in the periplasm. Whether or not the SBP has a similar responsibility in other ABC importer systems is an
area of active research.
To aid in the handoff of a substrate between the SBP and transporter, “scoop loops,” or short
periplasmic helices covalently attached to the TMDs, binds substrates from the SBP (Figure 1-6). This
interaction places the substrate in the transmembrane space of the transporter and moves the transport
process forward. These scoop loops have been found in the maltose and vitamin B12 transporters, however,
not all importers have these scoop loops as evidenced by the absence of a scoop-loop in the methionine
importer.21,22,23
The presence of an SBP adds an extra component to consider when dissecting the intermediate
states during a transport cycle.
Understanding how and when the
SBP binds to the transporter is
crucial

to

transporter

understanding

the

mechanism.

Functional studies thus far have Figure 1-6: Structures of substrate binding proteins of type I ABC importers.
MalE and BtuF have scoop loops while MetQ does not. Image taken directly from

been focused on determining the (22).
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binding affinities of the SBP to its transporter using mutational analyses, different nucleotide states, and
the presence and absence of substrate.22,24,25

1.4.5: Regulatory Domains
An additional component of some ABC importers are intracellular inhibitory domains. An ABC
importer uses the energy from ATP binding and hydrolysis to pump substrates against the concentration
gradient. If the cell has an adequate supply of a particular substrate, further import would waste cellular
energy. To prevent unnecessary import, transporters including the methionine and molybdate systems have
regulatory domains fused to the NBDs.28 At high intracellular concentrations, a substrate binds to the
regulatory domains and forces the transporter to adopt a conformation that prevents further ATP
hydrolysis.26,27 This phenomenon, termed transinhibition, acts as a regulatory mechanism that maintains
ideal concentrations of certain substrates inside the cell.

1.4.6: Subunits Forming Complete Transporters
The formation of the transmembrane domains, nucleotide binding domains, and for importers,
substrate binding proteins can require the production of five separate subunits: one subunit for each TMD
and NBD, and one subunit to form the SBP. This is the case for the methionine, maltose, and vitamin B12
transporters. However, there is a broad diversity in the number of subunits necessary to create a transporter.
For example, in some transporters, such as the FhuBC2D transporter (which transports several different
siderophores), the two TMDs are contained within one polypeptide. Some transporters, such as the TAP1
transporter, consist of two polypeptides, each containing a TMD and NBD. Interestingly, the TMD subunits
for the TAP1 transporter, which contribute to the process of exporting antigens in mammalian cells, are not
identical.28 Each TMD subunit is unique, making for an asymmetrical transmembrane domain. There are
also transporters, such as the P-gp transporter in human cells, that are entirely made from one unit. In
summary, despite the number of ways a transporter may be composed, ultimately, these transporters have
a base structure of two TMDs and two NBDs that come together to endergonically transport a diversity of
substrates: uniting them into one ABC superfamily.

1.5: ABC Transporter Types
There are three distinct groups of ABC transporters that are determined by the structural
architecture of the transporter. The transporters within each group not only share a similar structure, but
often times share similarities in finer mechanistic details. A study suggesting a mechanism for a transporter
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often suggests that the mechanism may
apply to all of the transporters in its group.
The three types of ABC transporter are type
I importers, type II importers, and ABC
exporters which are defined by their
transmembrane domain fold (Fig. 1-7).6

1.5.1: Type I Importer
Type I ABC importers, such as the
molybdate,
systems

maltose,
(ModABC,

and

methionine

MalFGK,

and

MetNIQ, respectively), contain 5-8 helices
Figure 1-7: Model structures for type I importer, type II importer,

per domain. All but one of the helices are and ABC exporters. Structure of transmembrane helices for Type I
importer (MetI), Type II importer (BtuC), and exporter (Sav 1866) taken
arranged perpendicular to the lipid bilayer. directly from (6).
One transmembrane helix per domain lies
more horizontally to the transmembrane cavity and wraps around the other helices, contacting each one.
Type I importers tightly couple ATP usage with the transport of relatively small molecules, including
sugars, amino acids, peptides, and compatible solutes.29,30,31,32 The TMDs contain a low-affinity binding
site for the substrate located approximately halfway through the membrane. The most well-studied type I
importer is the maltose transporter, which has been captured in several intermediate conformations during
the transport cycle. Crystal structures of this transporter reveal a distinct substrate binding site in the
transmembrane space between the TMDs, where specific non-covalent contacts form between maltose and
amino acid side chains within the permeation pathway.33

1.5.2: Type II Importer
Type II importers include the vitamin B12 transporter and various iron-containing transporters
(BtuCDF, HI1470/1), where the substrates are much larger and hydrophobic than those of type I importers.37
Type II ABC importers contain 10-12 transmembrane helices per domain, with all helices oriented parallel
to the transmembrane cavity. TM helices 5 and 10 mainly constitute the interface between the two TMDs,
which is responsible for forming the translocation pathway.34 These importers transport substrates that are
more scarce than type I importer substrates. This difference can explain why type II transporters have higher
substrate transport affinities than type I importers, with dissociation constants in the nano- to picomolar
range, while type I importers have dissociation constants in the micro- to nanomolar range.35,36,37,38 In type
II importers, the substrate is trapped in a non-specific hydrophobic cavity within the transmembrane
8

domains, in contrast to the specific binding interactions seen in type I transporters. The type II
transmembrane domains form two gates that regulate access to the interior hydrophobic pocket, termed the
cytoplasmic and periplasmic gates, based on their position within the lipid bilayer. These gates open and
close in a coordinated manner during substrate transport. When the periplasmic gates are open, substrate
can enter the transmembrane cavity from the outside of the cell. The periplasmic gates close before the
cytoplasmic gates open and release the substrate into the cell interior, and this coordinated opening and
closing ideally ensures unidirectional transport across the membrane (for a visual summary and further
description, see Figure 1-9 in Section 1.7.2).
These transporters may be less efficient at energy usage than type I importers, as suggested by
studies measuring the number of ATP molecules hydrolyzed per substrate transported. For example, for the
type II vitamin B12 transporter BtuCD, ~100 ATP molecules were hydrolyzed per vitamin B12 molecule
transported in vitro.39 The authors proposed that this large type II transporter may require numerous rounds
of ATP hydrolysis to enable conformational changes. Another hypothesis is that substrate can escape into
the extracellular matrix instead of passing through to the cytoplasm.40 With such a poor ATP to substrate
ratio, previous researchers proposed that the substrate may be released on both the extracellular end of the
transporter as well as the cytoplasmic end. This unproductive leakage may account for the high ATP
requirements for some type II importers.

1.5.3: Exporters
The third group of ABC transporter are the ABC exporters. They consist of 6 TM helices per subunit
or 12 helices per transporter which are arranged parallel to the transmembrane pathway. There is no binding
protein for ABC exporters, leaving the responsibility of substrate specificity solely up to the substrate
binding site within the TMDs. As with importers, the substrate forms noncovalent interactions with the 𝛼helices that line the transmembrane cavity in ABC exporters. There are a number of residues that can
interact with substrate allowing for several combinations of non-specific interactions in the TMDs. For this
reason, ABC exporters are often promiscuous in the substrates they export. Numerous molecules can be
identified as substrates for a single exporter since there are a multitude of residues that interact with the
substrate, allowing for a more diverse pool of substrates.41

1.5.4: Further Classification of Human ABC Transporters
The human genome contains 49 ABC genes that have been separated into seven subfamilies,
labeled A-G, based on their genomic data. These ABC genes can be alternatively spliced to form a variety
of transporters. Human transporters are often named based on their subfamily classification. For example,
the ABC transporter whose malfunction is linked to Tangier disease is called ABCA1 as it is a part of the
9

ABC subfamily A. Each subfamily contains a number of transporters that do not necessarily share similar
functions. A few subfamilies of note are subfamily B, which consists partially of transporters responsible
for multidrug resistance in cancer cells, and subfamily C, which contains the CFTR transporter whose
malfunction causes cystic fibrosis.42

1.6: Prevailing Transport Mechanism: Alternating Access Model
Transporters transition through multiple conformations per transport cycle, and two distinct
conformations provide a starting point for understanding ABC transport mechanism (Fig. 1-7).43 In the
inward-facing conformation, the TMDs are open to the cytoplasm, and the permeation pathway is
inaccessible from the periplasmic side of the lipid bilayer. In contrast, in the outward-facing conformation,
the TMDs are arranged with the permeation pathway open to the periplasm.
Observations of the inward-facing and outward-facing conformations can be incorporated into an
intuitive model for transport: the widely-accepted alternating access model. In this model, conformational
changes in the TMDs are driven by changes in the nucleotide state of the NBDs. In the absence of
nucleotide, the NBDs are separated, and the TMDs are in the inward-facing conformation. Binding of ATP
at the interface between the two NBDs triggers the rearrangement of the TMDs to the outward-facing
conformation. The energy from ATP binding is thought to provide the energy necessary to stabilize this
conformation. Upon ATP hydrolysis, the NBDs separate, which is coupled to a transition back to the
inward-facing conformation.43
The alternating access model can be applied to both ABC importers and exporters. For an ABC
importer, the SBP delivers the substrate to the transporter, driving formation of the ATP-bound outwardfacing conformation. Docking of the SBP and release of the substrate into the permeation pathway triggers
ATP hydrolysis, which in turn drives the rearrangement from the outward-facing to inward-facing
conformation. The substrate can then exit to the cytoplasm. The NBDs must release ADP and inorganic
phosphate before the next transport cycle can occur. For ABC exporters, the cytoplasmic substrate accesses
the TMDs in the inward-facing conformation. Substrate is transported once ATP binds to the NBDs, driving
a rearrangement to the outward-facing conformation. Following substrate exit, ATP is hydrolyzed and the
NBDs separate. ADP and inorganic phosphate are released, and the transporter returns to its inward-facing
conformation to repeat the cycle.6
In addition to the inward-facing and outward-facing conformations mentioned above, intermediate
states have been isolated and characterized in crystallographic and solution-based studies of various ABC
transporters. These intermediate conformations, include resting, pre-translocation, and post-hydrolysis
states, have placed a spotlight on further understanding and elucidating the mechanisms for different ABC
transporters.
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Figure 1-8: Alternating access model for ABC transport. ATP binding at the NBDs drives the outward-facing conformation
(left). The inward facing conformation is open to the cytoplasm (right). Substrate (red diamond) is transported across the membrane
upon changes in nucleotide state.

1.7: A Diversity of Mechanisms For ABC Transporters
While the alternating access model provides a starting point for understanding many ABC
transporter mechanisms, the intermediate steps in between the inward-facing and outward-facing
conformational states vary widely between transporters. Mechanisms can vary between different types of
transporters, between transporters that share the same transporter type, and even for a single transporter that
is studied in two different in vitro environments.

1.7.1: Proposed Mechanisms of a Type I Importer (Maltose Transporter MalFGK2)
The maltose MalFGK2 transporter is one of the most studied ABC transporters and is an example
of an ABC transporter with more than one proposed mechanism. The mechanism depicted in Fig. 1-8a was
proposed following studies with the transporter solubilized in the detergent n- dodecyl-β-D-maltoside. 46 In
this model, the MalE SBP binds maltose with high affinity and specificity in the periplasm and delivers it
to the membrane-embedded transporter. The SBP must bind maltose prior to binding to the transporter.
Substrate-bound SBP then binds the transporter in its nucleotide-free state. Once substrate-loaded SBP
forms a complex with the transporter, ATP binds to the NBDs and triggers the transition to the outwardfacing conformation via the coupling helices.
This change in TMD conformation causes the SBP to pry open, and with the aid of the scoop loop,
substrate is released to the transporter.23 The maltose substrate then binds to a low affinity binding site
within the TMDs. The transport of maltose is complete once ATP is hydrolyzed, causing the NBDs to
separate. Therefore, nucleotide hydrolysis drives the transporter into its inward-facing conformation,
allowing substrate to pass through into the cytoplasm of the cell. 23
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Figure 1-9. Possible mechanisms for maltose transport. (a) This mechanism was proposed based on structural studies of the
transporter solubilized in detergent. The image was taken directly from (45). (b) A second possible maltose transporter mechanism
based on functional studies of the transporter in lipid nanodiscs. The figure was taken directly from (46).

The original mechanism (Fig 1-8a)has been questioned as it was primarily based on structural
studies performed with the transporter in detergent micelles. In these crystallography studies, lattice
contacts and detergent effects may stabilize conformations that do not exist in vivo. Equilibrium studies of
the maltose transporter in lipid nanodiscs, a more accurate mimic of the lipid bilayer, indicating a distinct
mechanism for transport (Fig. 1-9b).44 Using crosslinking and fluorescence quenching experiments, Bao
and colleagues reported that ATP binding alone is enough to convert the transporter from the inward-facing
to the outward-facing conformation. Additionally, MalE can bind the transporter without maltose in the
binding pocket. Following complex formation, substrate binds to the complex and later crosses the
membrane upon ATP hydrolysis. However, in the presence of excess substrate, MalE sequesters substrate
and dissociates from the transporter, inhibiting further substrate transport.45

1.7.2: Proposed Mechanisms of a Type II Importer (Vitamin B12 Transporter BtuCD-F)
The vitamin B12 transporter is the most well-studied type II importer, playing a key role in
understanding the differences between type I and type II importers. One model for BtuCD-F transport was
based on structural studies of the transporter in detergent (Fig. 1-10).46 Crystal structures of BtuCD in
several intermediate states revealed three gates surrounding the hydrophobic cavity in the transmembrane
region: two on the cytoplasmic side, labeled cyto gates 1 and 2 (Fig. 1-10), and one on the periplasmic side
(peri gate). These gates block or allow substrate to pass through the transporter based on the nucleotide
state and presence of substrate. In this proposed mechanism, substrate-bound SBP BtuF docks onto the
transporter in its ATP-bound form (configuration 1 to 2). In this conformation, the cytoplasmic gates are
closed but the periplasmic gates are open to allow substrate into the transmembrane cavity. Next, substrate
is released from BtuF and trapped within the transmembrane cavity by cytoplasmic and periplasmic gates.
ATP is subsequently hydrolyzed, opening the cytoplasmic gates and allowing the substrate to pass into the
12

Figure 1-10: Proposed mechanism of the BtuCD-F importer based on structural studies. Yellow ball and stick represent
nucleotides, red ball and stick depict vitamin B12, blue lines depict TM helices 5 in each BtuC subunit, which form the gate and
cytoplasmic gate I. Magenta brackets depict cytoplasmic gate II, which is formed by the loop between TM helices 2 and 3, in each
BtuC subunit. Image taken directly from (47).

cytoplasm (configuration 2 to 3). BtuF dissociates from the complex and ATP binds to the transporter to
restart the transport cycle (configuration 4 to 1).
In contrast, a separate study with the transporter in both detergent micelles and liposomes resulted
in a different mechanism for BtuCD-F (Fig. 1-11).47 In this model, substrate-bound BtuF is able to bind to
BtuCD in its nucleotide-free state (configuration I). Upon binding to the transporter, the substrate is released
from BtuF, and vitamin B12 passes through the transmembrane domains while BtuF is still bound to BtuCD
(configuration II). ATP-binding and hydrolysis is necessary to dissociate the BtuCD-F complex and return
the transporter to its outward-facing, nucleotide-free state (configuration III and IV).

Figure 1-11: Proposed mechanism for the type II BtuCD-F importer from functional studies. The figure was taken directly
from (48).
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1.8: Transporter of Focus: Type I Methionine Importer MetNI
The focus of this thesis is to examine the mechanism of the Type I methionine importer MetNI,
specifically under what nucleotide and substrate conditions MetQ complexes with MetNI (Fig. 1-11).
Although the transporters linked to disease in humans are ABC exporters, ABC importers are seen as
reliable models for exporter activity due to homology (25-30%) between the two classes of transporters,
especially in the NBDs.48 Here we utilized the methionine transport system from Escherichia coli, which
was first studied by Kadner and Watson in 1974.49

A

MetQ

B

MetI

MetN

Figure 1-12: Crystal structures of the methionine importer MetNI. (a) The outward-facing conformation of MetNI in complex
with the substrate-binding protein MetQ (22). MetQ is pictured in yellow, the TMDs are pictured in blue, and the NBD and C2
domains are pictured in purple. (b) The inward-facing, transinhibited conformation of MetNI(53).

1.8.1: MetN: The Nucleotide Binding Domain
The nucleotide binding domain of MetNI is referred to as MetN. These subunits are identical to
each other, however each is a separate polypeptide. To form a complete nucleotide-binding domain, the
two polypeptides come together, associating to form a homodimer. There are a number of amino acids
within the NBDs that interact with ATP, and two crucial amino acids are a glutamate at position 166 (E166)
and a lysine at position 44 (K44). E166 is part of the Walker B motif (introduced in Section 1.4.2) and is
necessary for ATP hydrolysis. The glutamate acts as a general base and polarizes H 2O for nucleophilic
attack of the 𝛾-phosphate. As depicted in Figure 1-13c, substituting glutamate with a glutamine (E166Q)
residue hinders the ability to hydrolyze ATP without diminishing the binding of ATP (Fig. 1-13).50
Glutamine is chosen as a substitute due to its similar size and structure to glutamate. The K44 amino acid
located within the Walker A motif of MetNI has been proposed to play a central role in ATP binding.
Substituting alanine for the lysine residue in the Walker A motif of the MJ0796 transporter reduces ATP14

binding by 15-fold.50 This NBD mutant is a key component in locking a MetNI transporter in its nucleotidefree state.
An additional structural detail for the ATP-bound, outward-facing conformation of the MetNI
transporter is the inability of the alanine-299 residues at the intersection of the adjacent NBDs to hydrogen
bond(Fig. 1-13b) The distance between these residues is too far, allowing the transporter to remain in the
outward-facing conformation. Once these residues come in closer proximity to each other (3 Angstroms or
less), they initiate a hydrogen bonding complex that forces the transporter in the inward-facing
conformation (for further details and images, see Section 1.8.3 and Figure 1-14).

A

B

C

Figure 1-13: Uninhibited, outward-facing conformation of MetNI. (a) Crystal structure of ATP-bound MetNI in complex
with apo MetQ. The approximate location of the alanine-299 residues and the E166Q mutation are boxed in red and blue,
respectively (22). (b) Adjacent alanine-299 residues are unable to hydrogen bond in the outward-facing conformation. (c)
ATP𝛾S bound (right) bound to the E166Q residue (left) within the NBDs. All measurements are given in angstroms.

The ATP-binding pockets of MetN have a reported Km of 330 ± 20 µM with ATP.27 The Km value
is the concentration of substrate required for the transporter to achieve half of its Vmax value. In the case of
ATP, a transporter’s Vmax value is the maximum number of ATP the transporter hydrolyzes per minute. For
this system, the lower the Km value, the higher the affinity the transporter has for ATP. With typical
intracellular ATP concentrations between 1-10 mM, MetNI’s affinity for ATP is strong enough for the
transporter to operate at its maximum capacity in vivo.51 ATP-binding between the MetN subunits has been
found to be cooperative (n = 1.7 ± 0.1) meaning that the affinity for ATP increases when one of the binding
sites has bound ATP. This cooperativity suggests that the two ATP sites communicate with each other
during the transport cycle.

1.8.2: MetI: The Transmembrane Domain
The two subunits that form the transmembrane region of MetNI are identical to each other (Fig. 111, blue). Each MetI subunit is composed of 5 helices. Unlike other ABC transporters, there are no MetNI
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crystallographic structures with substrate bound within the TMD, however, there is a proposed binding site
for L-methionine in the transmembrane region. The pathway through the membrane created by the interface
between the two MetI subunits is thought to be selective for methionine derivatives.22

1.8.3: C2 domain: The Inhibitory Domain of MetNI
An added feature for many ABC importers is regulation of transporter activity. In the case of the
MetNI transport, unregulated activity could lead to unnecessarily high levels of intracellular methionine
and wasteful usage of ATP. Regulation of transport was first observed in in vivo studies by Kadner and
Watson in 1975, in which a rapid decrease in methionine transport was observed as intracellular methionine
increased.52 Based on crystallography studies, a transinhibition mechanism was proposed, in which Lmethionine binding traps MetNI in the inward-facing conformation. This regulatory strategy was further
supported by in vitro biochemical studies in which L-methionine was shown to act as a non-competitive
inhibitor of ATP.53 The simplicity of this mechanism allows the cell to avoid more arduous regulatory
processes, such as protein degradation and transcription regulation, which require longer response times
and are energetically demanding processes. The presence of an allosteric regulatory mechanism prevents
wasteful ATP hydrolysis and prevents the build-up of substrate inside of the cell.
An arginine residue at position 295 in the C2 regulatory domain of MetNI is crucial for
transinhibition.22 The side chain of arginine forms hydrogen bonds with the N-terminus of the L-methionine
substrate (Fig. 1.14c), which in turn promotes a hydrogen bonding network between the peptide -NH and -
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Figure 1-14: Transinhibited, inward-facing conformation of MetNI. (a) Crystal structure of MetNI with L-Met bound to its
C2 domains(53). The approximate location of the N299 and Q166 residues are boxed in red and blue, respectively. (b) Adjacent
alanine-299 residues that hydrogen bond in the transinhibited conformation. (c) The N295A side chain from one C2 domain
(gray) forms hydrogen bonds with L-Met (cyan). All measurements are given in angstroms.
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CO groups on the alanine amino acids located at position 299 in the adjacent NBDs (Fig. 1.14b). In
comparison, when there is no L-Met bound to the C2 domains, the adjacent alanine amino acids at position
299 are too far to form a hydrogen bond (Fig 1-13, allowing the structure to more easily maneuver into the
outward-facing conformation network locks the C2 domains together, preventing the NBDs from coming
together to form the ATPase sites. A previously identified MetNI mutant N295A greatly reduces the binding
affinity of L-Met for the C2 domains, nullifying the transinhibitory effect of intracellular methionine. 22
1.8.4: MetQ: The Substrate Binding Protein of MetNI
The MetNI transporter can be found in Gram-negative bacteria, and thus the substrate-binding
protein of the transporter, MetQ, resides in the periplasmic space. MetQ preferentially binds L-Met over
related methionine derivatives. MetQ from Neisseria meningitides has a very high affinity for L-Met, with
a Kd value of 0.2 nM. The equilibrium constant Kd is a constant that quanitifies the affinity between two
molecules. The lower the Kd value, the stronger the affinity between two molecules. For example, MetQ
has a much stronger affinity for L-Met (Kd of 0.2 nM) than it does for substrate D-Met with a Kd of 3.5
µM.54 This preference for L-Met over D-Met is likely due to the cell’s preference for L-oriented amino
acids. All synthesized proteins are made with L- amino acids. Converting D-Met requires the presence of
racemase enzymes that are not always present.
MetQ, like other SBPs, binds substrate in a Venus flytrap mechanism (Fig. 1-15a).19,54 MetQ binds
to MetNI in both its apo and its substrate-bound form, although the technique used in this published study
is not widely accepted by the biochemistry community. Nonetheless, L-Met bound MetQ a ~40-fold weaker
binding affinity to MetNI than apo MetQ.55 The MetQ N229A mutant has a greatly reduced binding affinity
to methionine derivatives and is often utilized as an easily producible apo MetQ substitute. MetQ N229A
replaces the arginine amino acid at location 229 and replaces it with an alanine amino acid. The positivelycharged side chain on arginine has strong ion-dipole interactions with the sulfur atom of the methionine

A
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Figure 1-15: L-Met bound MetQ. (a) Crystal structure of L-Met bound MetQ (55) . (b) Image of the hydrogen bonding
interactions between residue N229 and L-Met (cyan).
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side chain (Fig. 1.15b). Replacing the arginine side chain with the alanine side chain causes the observed
reduction in MetQ -methionine binding affinity.

1.9: Possible Mechanisms for Methionine Importer MetNI
Two different mechanisms have been proposed for MetNI transport, as described below. These
mechanisms are very similar to the seemingly opposed mechanisms of the maltose transporter, and it is
hypothesized that both mechanisms may be utilized for methionine import.

1.9.1: Canonical Model
Cellular proteins only utilize L-amino acids to construct proteins. For this reason, cells largely
prefer to import L-amino acids to conserve energy rather than reconfigure amino acid stereocenters. In the
canonical model, L-methionine is the preferred substrate for delivery into the cell. The transport cycle
follows the original model proposed for the maltose transporter based on studies of the transporter in
detergent. In this model, MetQ scavenges the periplasmic space until it binds L-Met. L-Met loaded MetQ
then delivers the substrate to membrane-bound MetNI in its nucleotide-free state (Fig. 1-16). Following
MetNI-Q complex formation, ATP binds to the NBDs, driving the transporter into its outward-facing
conformation. This conformational change triggers L-Met release into the permeation pathway. ATP is then
hydrolyzed, allowing the transporter to return to the inward-facing conformation, thereby transporting LMet into the cell. Lastly, ADP dissociates from the NBDs and the transporter returns to the apo state, ready
to engage in the next transport cycle.24

Figure 1-16: The canonical model for the MetNI transporter. In this model, MetNI-Q transports substrate L-Met.
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1.9.2: Non-Canonical Model
A second possible mechanism involves the transport of methionine derivatives that have a lower
binding affinity to MetQ, such as D-Met (Fig. 1-16). This mechanism, referred to as the non-canonical
mechanism, is very similar to the mechanism proposed for the maltose transporter based on studies
performed with the transporter in nanodiscs. The main difference between the canonical and non-canonical
model is in steps 1 and 2. In the non-canonical model, apo MetQ binds to ATP-bound, MetNI before L-Met
later binds to pre-complexed MetQ. D-Met arrives at the transporter-binding protein complex, where it is
able to travel through a small pathway embedded in the MetQ protein. MetQ then twists 24° around an axis
perpendicular to the interface between the two lobes of the protein. This twist creates an opening for D-Met
to pass through MetQ, a mechanism not yet found in other ABC transporters, giving D-Met a path to the
transmembrane cavity. From here, the mechanism behaves identically to the canonical mechanism in which
ATP is hydrolyzed, driving the transporter to its inward-facing conformation and allowing substrate to
travel into the cell.22
The proposed non-canonical mechanism is one that complements the classical mechanism and does
not necessarily contradict it. Nguyen and colleagues propose that in situations of L-Met scarcity, the
transporter will be biased towards the non-canonical mechanism and import less desirable methionine
derivatives.22 In this circumstance, the MetNI-apo MetQ complex is formed first and awaits arrival of a
substrate molecule such as D-Met. Upon transport of D-Met, apo MetQ will dissociate from MetNI,
rendering it available to roam the periplasm in search of more substrate. If L-Met becomes available, MetQ
will bind to the substrate with high affinity and initiate the canonical mechanism. If L-Met is absent, apo
MetQ will return to form a complex with MetNI, and pending L-Met derivative arrival, will begin the noncanonical mechanism. The combination of the canonical and non-canonical pathways would allow the

Figure 1-17: The non-canonical model of the MetNI transporter. This model is proposed to predominantly transport methionine
derivatives such as D-Met (orange diamond).
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MetNI transporter to rapidly adjust its substrate consumption, ensuring cell survival under different
environmental conditions.22

1.10: Experimental Approach and Key Questions Addressed in This Work
Measuring binding affinities between an ABC transporter and its cognate binding protein is a key
step in dissecting transport mechanisms. Our research efforts were focused on the requirements for the
complex formation between the MetNI transporter and the MetQ substrate binding protein. We developed
a solution-based technique to quantify the strength of this interaction under varying conditions, as detailed
below.

The development of fluorescence anisotropy as a robust technique to study ABC transporter mechanism.
X-ray crystallography studies have been crucial in understanding ABC transporter function;
however, these studies place the transporter in a highly artificial environment. Solution-based
thermophoresis titrations assess ABC transporter binding affinities, however, the method has failed to reach
widespread approval in the research community. Lastly, surface plasmon resonance has been utilized to
assess binding affinities of other transporter complexes, but has failed to produce reliable data with the
MetNI transporter.
Another commonly used method to study binding affinities in biochemistry is fluorescence
anisotropy. Briefly, this method relies on the relationship between the size of a fluorescent molecule and
its change in polarized light emission. When a stationary fluorescent molecule is excited, it emits a photon
of light that travels on the same axis as the excitation photon. However, molecules in solution are not
stationary. In the elapsed time between light absorption
and emission (10-9 to 10-15 seconds) the molecule
tumbles in solution. The light emitted is consequently
depolarized due to this rotation. The smaller the dye
molecule, the more it will rotate in solution and the more
depolarized the emitted light.56
A fluorescence anisotropy study of the OppA
ABC transporter system, which is responsible for the
transport of the nine-amino-acid peptide bradykinin, had
a series of precise binding affinities of two biomolecules
in a variety of pH and temperature conditions. Following
in their footsteps, our research aim was to measure the
Figure 1-18: Schematic of anisotropy assay for the

binding affinity between the MetNI transporter and the study of MetNI-Q complex formation.
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MetQ SBP, (Fig. 1-17) using fluorescence anisotropy for the first time. We successfully measured the K d
of MetNI-Q complex formation under different conditions with a relatively small standard deviation in the
results. Our results have suggested the presence of both the canonical and non-canonical model for
methionine transport.

Which nucleotide states promote MetNI - Q complex formation?
In the proposed canonical mechanism for methionine import, MetQ binds to MetNI in its
nucleotide-free state. This mechanism follows the original model for the maltose transporter, which was
proposed based on studies performed in detergent. However, a crystal structure of the MetNI-Q complex in
the apo nucleotide form has not been determined, and functional studies have not been able to support its
possible existence. A more recent mechanism of the maltose transporter studied in lipid nanodiscs may
provide more biologically relevant insight. In this mechanism, ATP-binding is a pre-requisite for the SBP
to bind to the transporter.
To examine the role of nucleotide state in MetNI-Q complex formation, we measured the Kd value
of the MetNI-Q complex in the presence of various nucleotides. Using our fluorescence anisotropy assay,
we report a significant difference in Kd values based on the nucleotide state, with complex formation
showing a strong preference for the ATP-bound state. This finding sheds light on the role of ATP binding
in methionine transport.

Is MetQ bound to substrate prior to complex formation?
The canonical model for transport proposes that MetQ is bound to L-Met prior to forming a
complex with MetNI. The affinity between MetQ and L-Met is extremely tight, with a Kd value of 0.2
nM60, and the crystal structure of isolated MetQ bound to L-Met has been solved. However, the only
existing crystal structure of the MetNI-Q complex was solved using a mutant form of MetQ that cannot
bind substrate. Microscale thermophoresis experiments determined that this interaction was approximately
40 times stronger than with wild-type MetQ bound with L-Met (Kd = 27 ± 9 nM vs. 1100 ± 300 nM,
respectively). While the discovery brought attention to the possibility of two different mechanisms for
transport, the method used to determine the binding affinities has yet to be widely accepted, and thus these
binding affinities are in question.
To examine the difference in binding affinities between apo and L-Met bound MetQ with MetNI
in the presence of ATP, fluorescence anisotropy was utilized. We find a modest difference between the
affinities of the two complexes, which can be incorporated into pre-existing models to explore the cellular
preferences for L-methionine versus D-methionine.
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Does binding of L-methionine to the C2 regulatory domains inhibit complex formation?
The elegant in vivo experiments conducted by Kadner demonstrated the transinhibition property of
MetNI. Based on the crystal structure of MetNI, in conjunction with functional studies, it has been proposed
that intracellular L-Met binds to the C2 domains of MetNI, forcing the complex into an inward-facing
conformation. While the NBDs of the MetNI are separated in this conformation, it is unclear as to whether
or not this arrangement precludes the binding of MetQ.
In this study, we are able to detect the dissociation of the MetNI-Q complex upon addition of excess
L-methionine. While this result is very preliminary, it suggests that the intracellular level of substrate can
prevent the binding of MetQ on the periplasmic side of the cell. This mechanism, in conjunction with the
physical separation of the NBDs, could work to limit the intake of excessive L-methionine.

1.11: Summary
ABC transporters are crucial to cell homeostasis and cell viability in all kingdoms of life.
Malfunctions in these transporters are linked to a number of conditions including cystic fibrosis, Stargardt’s
disease, and multi-drug resistance. In order to treat these ailments, scientists must first understand the
mechanism of ABC transporters. A plethora of knowledge has already been discovered regarding ABC
transporters, including their atomic structure, conformational states, and regulatory strategies. While the
strides made to understand ABC transporters have been significant, there are details that have yet to be
elucidated. To investigate these transporters, we address specific questions about the bacterial methionine
importer MetNI. This importer contains the highly-conserved features found in human ABC exporters, and
previous work has established robust expression and purification protocols. In this thesis, we specifically
aim to determine the requirements for the formation of the transporter-substrate binding protein complex,
MetNI-Q. Using a fluorescence anisotropy assay, we examine the nucleotide and substrate states that best
promote complex formation and how the binding of L-Met to the C2 regulatory domains affects MetNI-Q
stability. Our findings not only address these questions, but also offer more directions for future researchers
to investigate.
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Chapter 2: Methods

2.1: Expression of MetNI and MetQ Proteins
Previously published plasmids were gifts from Douglas Rees (Caltech) and were expressed in E.
coli BL21-Gold DE3 cells (Agilent). MetNI and MetQ constructs were transformed by mixing 25 µL of
cells with 1 µL of the respective plasmid (~100 ng/µL) and incubated 10 min on ice. The cells were heat
shocked for 20 seconds in a 42°C bath and cooled for two min on ice. Two hundred µL of LB (Lysogeny
Broth) media were added before shaking at 225 rpm at 37°C for 30 min. Two hundred μL of cells were
grown on agar plates with 200 μg/mL ampicillin at 37°C overnight.
Five mL starter cultures were made with LB media inoculated with a single colony of the
transformed cells. Starter cultures contained 200 µg/mL of ampicillin and were left to grow overnight at
37°C and 225 rpm. Starter cultures were added to Fernbach flasks containing 1L of Terrific Broth media
(24g/L yeast extract, 12 g/L tryptone, 72 mM K2HPO4, 17 mM KH2PO4 and 0.5% glycerol, autoclaved)
with 100 µg/mL of ampicillin to begin large-scale growth. Large-scale growth was performed at 37°C and
180 rpm. To check for growth, the optical density at 600 nm was monitored by checking the optical density
of 1 mL samples. Once the optical density reached a value of 2, the cells were induced with a final
concentration of 1 mM IPTG for 1 hour. Cultures were pelleted by centrifuging at 13,500 rpm at 4°C using
a Beckman Avanti J-25 I floor centrifuge and a JLA 16.25 rotor. Pellets were stored at -80°C until protein
purification was performed.

2.2: Transformation of MetNI Double Mutants (Lm N295AE166Q Lu N295A & Lm N295A Lu
N295A)
The procedure for the expression of MetNI double mutants were identical to that above but with
minor modification. One hundred μL of E. coli BL21-Gold DE3 cells were transformed with 2 µL of both
the Lm and Lu plasmids (~100 ng/µL). The mixture was set on ice for 10 min before being heat shocked
for 20 seconds in a 42°C bath. The cells were then cooled on ice for 2 min before addition of 1 mL of SOC
(Super Optimal broth with Catabolite repression) media and incubation at 37°C and 225 rpm for 1 hour.
Two hundred μL of cells were plated onto an agar plate containing 200 μg/mL of ampicillin and kanamycin
and left to grow overnight at 37°C.

2.3: Purification of MetNI
All strains of the MetNI transporter, as well as the MetQ SBP, were purified using an ÄKTA Pure
FPLC System (GE Healthcare). The entire procedure was kept on ice or performed at 4°C unless noted
otherwise. Fifteen g of cells were homogenized in 150 mL of MetNI buffer {50 mM
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[tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS) pH 8.5, 250 mM NaCl, and 1% n-Dodecyl
β-D-maltoside detergent (DDM; Anatrace)}. Deoxyribonuclease (10 µg/mL) (Sigma-Aldrich), lysozyme
from bovine pancreas (10 µg/mL; Sigma-Aldrich), and PMSF (1µM) were added once the cells were
homogenized in buffer. DDM detergent was added to a 1% mass-to-volume ratio (1.5g in 150 mL), not
including the DDM present in the MetNI buffer, to the cell lysate.
The lysate was stirred for 20 min before sonication with a flat tip sonicator (Branson Ultrasonics
Sonifier), on ice, at 20% bursts of 50 kHz for 45 seconds followed by 90 seconds of cooling for 7 cycles,
for a total of 5 min and 15 seconds of sonication. The solution was then centrifuged at 19,000 rpm for 20
min in a Beckman Avanti J-25 I centrifuge and a JLA-20 rotor. Imidazole was added to the supernatant to
a final concentration of 25 mM. The mixture was loaded onto a Ni-NTA HisTrap 5mL HP column (GE
Healthcare) using MetNI buffer containing 25 mM imidazole at 2 mL/min as the mobile phase. The column
was washed with MetNI buffer with 25 mM imidazole until the UV reading reached the baseline level at
280 nm, and the same processes were repeated for with MetNI buffer containing 75 mM imidazole. Protein
was eluted with MetNI buffer containing 350 mM imidazole. The eluent was injected onto a HiPrep 26/10
Desalting column (GE Healthcare). Collected peak fractions (10-12 mL) were pooled and frozen in liquid
nitrogen before storing at -80°C overnight.
Sixteen hours later, the eluent was centrifuged in 5 min intervals at 3500 rpm and concentrated to
5 mL or less with an Amicon Ultra-15 centricon tube with a 100 kD cutoff (Millipore) in an Eppendorf
Centrifuge 5804R. The concentrated eluent was injected onto a Superdex 200 pg 16/600 sizing column (GE
Healthcare). Peak fractions, appearing around 60 mL elution volume, were collected and added to a new
Amicon Ultra-15 centricon tube with a 100 kD cutoff. The protein was centrifuged at 3500 rpm at 4°C until
the protein reached a concentration between 10-20 mg/mL which was measured at 280 nm using an Implen
Nanodrop N50. The absorbance was divided by the extinction coefficient of MetNI (83365 M -1 cm-1) and
multiplied by its molar mass (122034.85 g/mol) to determine the concentration in mg/mL.

2.4: Purification of MetNI Chimeras
The initial purification of MetNI chimeras followed the previous procedure for MetNI purification
up to elution from the desalt column. From there, the method diverges with the goal of removing non-FLAG
tagged MetNI transporters from the final product.
The eluent from the desalting column was loaded onto a 20-mL FLAG affinity column (SigmaAldrich). Once the UV peak from contaminant protein had passed through the column, an additional 30 mL
of buffer was flowed through the column before the protein was eluted with 10 μg/mL FLAG peptide in
MetNI buffer. To remove the FLAG peptide, the peak elute fractions were collected and concentrated from
the FLAG affinity column in an Amicon Ultra-15 centricon tube with a 100 kD cutoff to less than 5 mL
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before injecting the solution onto a Superdex 200 pg 16/600 sizing column (GE Healthcare). The peak
eluted fractions were collected, concentrated in a separate Amicon Ultra-15 centricon tube with a 100 kD
cutoff to a concentration close to 10 mg/mL before being flash frozen in liquid nitrogen and stored at -80°C.

2.5: Purification of MetQ
Eighteen grams of pelleted BL21 cells were homogenized (by hand, with a spatula) in 10 mL of 40
% sucrose, 1 mM EDTA, and 10 mM Tris pH 7.5 and then stirred at room temperature for 1 hour. The cells
were then shocked by adding 500 mL of ice-cold deionized water. After stirring for 10 min at 4°C, buffer
components were added to a final concentration of 25 mM Tris pH 7.5, 150 mM NaCl, 5 mM BME, and
17 mM imidazole. The resulting suspension was centrifuged at 15,817 rpm (37,500 x g) for 30 min. The
lysate was loaded onto a 5 mL Ni-NTA column equilibrated in MetQ buffer (25 mM Tris pH 7.5, 150 mM
NaCl, 5 mM BME). The column was washed with 10 column volumes of MetQ buffer with 17 mM
imidazole. The protein was eluted with MetQ buffer containing 400 mM imidazole. The pooled fractions
were injected onto a HiPrep 26/10 Desalting column previously equilibrated with MetQ buffer. The peak
fractions were pooled and frozen in liquid nitrogen and stored at -80°C overnight.
Sixteen hours later, the pooled fractions were concentrated in an Amicon Ultra-15 centricon tube
with a 10 kD cutoff until the volume was at or below 5 mL. The concentrated protein solution was then
injected onto a Superdex 200 pg 16/600 sizing column. Peak fractions were collected (elution volume ~9
mL) and concentrated in an Amicon Ultra-15 centricon tube with a 10 kD cutoff until the concentration
was 10 mg/mL. To calculate protein concentration, the absorbance was recorded at 280 nm with an Implen
Nanodrop N50. To convert the concentration into mg/mL, the absorbance was divided by the extinction
coefficient for MetQ (20400 M-1 cm-1) and multiplied by the molar mass (29431.65 g/mol).

2.6: SDS-PAGE of Purification Process
Samples collected throughout the MetQ and MetNI purification process were analyzed for their
protein content via SDS-PAGE. The samples collected for the gel were the lysate, pellet, and supernatant
before injection onto the Ni-NTA column plus the flow-through, wash, and eluent solutions from the NiNTA column and finally the desalt and sizing elutions. All samples prepared for the gel had a final volume
of 24 μL, where 12 μL of each sample was 2x loading buffer (4% SDS, 100 mM Tris-HCl, 20% glycerol,
0.2% bromophenol blue, 200 mM dithiothreitol) and the other 12 μL of the gel sample contained different
ratios of the collected sample with its corresponding buffer depending on the sample (MetNI buffer for a
MetNI purification analysis, MetQ buffer for a MetQ purification analysis). For the lysate, pellet, and sizing
eluent samples, one μL of the final sample volume was the eluent while the remaining 11 μL of the sample
was buffer solution. For the supernatant, flow-through, wash, Ni-NTA, and desalt eluent samples, 12 μL of
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each sample was added to each SDS-Page sample prep. After the preparation of each sample, the samples
incubated at 95ºC for 5 min before loading.
Ten μL of every prepared sample and a protein ladder (Bio-Rad) were loaded into separate wells
of a Mini-Protean TGX gel (Bio-Rad). The gel was placed into a gel box and filled with 1x SDS running
buffer (1 g/L sodium-dodecyl-sulfate, 3 g/L Tris (hydroxymethyl) aminomethane, 14.4 g/L glycine). The
gel was run at 200 volts for 30 min. The gel was then placed into a container with Coomassie Blue staining
solution (40% methanol, 10% acetic acid, 1g/L brilliant Coomassie blue staining powder) for 30 min with
agitation. The Coomassie stain was removed, and destaining solution was added (40% methanol, 10% acetic
acid) before the gel was agitated for an hour. The gel was then removed from the destaining solution and
imaged using a ChemiDoc MP (BioRad).

2.7: ATPase assays
To measure the rate of ATP hydrolysis, a commercially available coupled enzyme system was
utilized (Enzchek Phosphate Assay Kit, Invitrogen). In the presence of free phosphate, the enzyme purine
nucleoside (PNP) converts the substrate 2-amino-6-mercapto-7-methylpurine riboside (MESG) into free 2amino-6-mercapto-7-methylpurine, which absorbs light at 360 nm.
To convert the measured absorbance to concentration of Pi, phosphate standard curves were
generated. A phosphate standard curve was prepared with 100 µL wells containing Pi concentrations of 500
µM, 250 µM, 100 µM, 50 µM, 10 µM, and 0 µM. Each reaction contained 55 mM Tris pH 7.5, 5 mM TAPS
pH 8.5, 0.055% DDM, 55 mM NaCl, 1 mM BME, 5 mM MgCl2, 200 µM MESG, 300 nM MetNI and 1U
per reaction of PNP. A best-fit line of the data provided a reliable constant to convert AU to concentration
of Pi.
To measure the ATPase activity of MetNI, 90 μL reactions were prepared in a Greiner black-clear
bottom 96-well plate for absorbance measurement in a Tecan Infinite 200 plate reader. Ten μL of 50 mM
MgCl2 was injected into each well to initiate the reaction, and the absorbance at 360 nm was recorded every
20 seconds for a total of 500 seconds. The final buffer condition for each sample was identical to samples
of the phosphate standard assay. Plots of AU vs. time (seconds) were graphed and the region with the
steadiest linear trend (usually from 300s-500s) were analyzed to find the change in AU/sec. This slope was
converted to find kobs, or ATP hydrolyzed/minute per transporter, using the equation
𝐴𝑈
𝑠𝑒𝑐

∗

𝑀 𝑃𝑖
𝐴𝑈

∗

60 𝑠𝑒𝑐
1 𝑚𝑖𝑛

∗

1
3∗10−7

𝑀 𝑀𝑒𝑡 𝑁𝐼

=

𝑃𝑖
𝑚𝑖𝑛∗𝑀𝑒𝑡𝑁𝐼

(Equation 1)

where the M Pi/AU component of this equation is the slope from the phosphate standard curve.
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Plots of kobs versus the concentration of ATP were fit to the following equation

𝑘𝑜𝑏𝑠 =

𝑘𝑐𝑎𝑡 ∗[𝐴𝑇𝑃]𝑛
𝑛 +[𝐴𝑇𝑃]𝑛
𝐾𝑚

(Equation 2)

where kcat is the catalytic rate constant for ATP hydrolysis, Km is the concentration of ATP at which ATPase
activity equals half of kcat, and n is the Hill coefficient. In this system, Km (or Michaelis constant) is a
measure of the affinity of MetNI for ATP, and the Hill coefficient is a measure of the cooperativity of
ATPase activity between the two nucleotide binding sites.
ATPase assays to determine the affinity of L-Met for the C2 inhibitory domains of MetNI were
performed as above except ATP was kept constant at 5 mM ATP while L-Met varied from 0 mM to 5 mM.
Data from ATPase assays were fit to the equation

𝑘𝑜𝑏𝑠 =

𝑘𝑐𝑎𝑡
[𝐿−𝑀𝑒𝑡]𝑛
(1+
)
𝐾𝑖 𝑛

(Equation 3)

where Ki (the inihibition constant) is the concentration of L-Met at which kobs is half of kcat, and n is the
Hill coefficient for the cooperativity of L-Met binding. All data fitting was conducted using Prism Version
7 software.

2.8: MetQ Labeling
This procedure largely follows that offered by Thermo Fisher; the manufacturer of the fluorescent
dye used in the procedure (fluorescein 5-maleimide). One mL of ~10 mg/mL purified MetQ was injected
onto a 5-mL HP Desalting column equilibrated in labeling buffer (25 mM Tris pH 7.0, 150 mM NaCl, 5
mM EDTA, 10 mM TCEP). Peak fractions were pooled, and labeling buffer was added for a final
concentration of MetQ between 30-40 µM. Solid fluorescein 5-maleimide (FW = 427 kD, Thermo Fisher)
was added to a final concentration of 1 mM (25x the molar ratio of MetQ). The solution was continuously
inverted at room temperature for 2 hours. The labeling reaction was then quenched by adding betamercaptoethanol to a final concentration of 100 mM (FW = 78 g/mol, Bio-Rad) and inverted at room
temperature for an additional 15 min. Next, the solution was injected onto a TALON 2-mL disposable
gravity column with 200 µL of Ni-NTA (Qiagen) beads that had been previously equilibrated with MetQ
buffer. The column was washed with 10 mL of MetQ buffer before elution with MetQ buffer containing
400 mM imidazole. The eluted protein was injected onto a 5 mL HP Desalting column previously
equilibrated with MetQ buffer. The peak fractions were collected and pooled together. The labeling
efficiency was determined using the equation
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𝐴494
𝜀

∗

𝑀𝑊 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑚𝐿

=
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𝑚𝑜𝑙𝑒𝑠 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛

(Equation 4)

in which A494 is the absorbance of the solution at 494 nm (peak absorbance wavelength of fluorescein 5maleimide), ε is the extinction coefficient of fluorescein 5-maleimide (90,000 M-1 cm-1), MW is 29431.65
g/mol (molar mass of MetQ), and mg protein/mL is the measured concentration of MetQ.

2.9: Anisotropy to Determine Kd of MetQ - MetNI In the Presence of ATP
A detailed step-by-step procedure for this section can be found in the Appendix.
Purified MetNI and a 1:5 dilution of purified maleimide-labeled MetQ (diluted with MetQ buffer)
were separately spun at 90,000 rpm for 20 min at 4°C using an Optima TLX Ultracentrifuge in a TLA-100
rotor to remove any aggregates (Beckman). Following centrifugation, the concentration of each protein was
determined by measuring the absorbance at 280 nm. 25 µL solutions were prepared on ice with final
concentrations of 3 mM ATP, 3 mM EDTA, 0.06% DDM, 150 mM NaCl, 57.5 mM Tris pH 7.5, and 10
mM TAPS pH 8.5.
For MetQ N229A – MetNI E166Q experiments, the final concentration of MetNI E166Q varied
from 0 – 10 μM. For MetQ WT – MetNI E166Q experiments, final concentrations of MetNI E166Q varied
from 0 – 20 μM.
Once reaction mixtures were prepared on ice, 20 µL of each solution were transferred to a blackclear bottom Greiner 384-well plate. The solutions were placed in the Spectramax Gemini plate reader
preset to 37°C for 10 min. After incubation, fluorescence polarization (FP) values were recorded with the
sensitivity of the sensor set to high.
FP values and their corresponding MetNI concentrations were plotted and analyzed using Prism.
First, relative Bmin, Bmax, and Kd values were determined using the equation

𝐹𝑃 =

𝐵𝑚𝑎𝑥 ∗[𝑀𝑒𝑡𝑁𝐼]
𝐾𝑑 +[𝑀𝑒𝑡𝑁𝐼]

+ 𝐵𝑚𝑖𝑛

(Equation 5)

in which FP is the recorded fluorescence polarization value, Bmax is the maximum FP asymptote, Bmin is the
minimum FP asymptote, and Kd is the MetNI concentration at which 50% of the maximum change in FP
has been reached.
FP values were then converted to fraction bound using the equation
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𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑜𝑢𝑛𝑑 =

𝐹𝑃−𝐵𝑚𝑖𝑛

(Equation 6)

𝐵𝑚𝑎𝑥

Fraction bound values were then plotted as a function of MetNI concentration and fit to the equation

𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑜𝑢𝑛𝑑 =

[𝑀𝑒𝑡𝑁𝐼]
𝐾𝑑 +[𝑀𝑒𝑡𝑁𝐼]

(Equation 7)

with fraction bound values produced by calculations using Equation 6, and Kd representing the
concentration of MetNI at which fraction bound is equal to 50%.

2.10: Using Fluorescence Anisotropy to Determine Kd of L-Met to MetQ N229A - MetNI E166Q
Complex
The procedure to determine the Kd of L-Met for the MetQ N229A – MetNI E166Q complex was
nearly identical to determining the Kd of MetQ – MetNI in the presence of ATP with a few changes. Instead
of varying the concentration of MetNI, each reaction contained 5 μM MetNI E166Q and 20 nM MetQ
N229A. The concentration of L-Met varied from 0 – 20 μM. The equation to calculate Bmin, Kd, and Bmax
was modified to

𝐹𝑃 = 𝐵𝑚𝑎𝑥 −

𝐵𝑚𝑎𝑥 ∗[𝑀𝑒𝑡𝑁𝐼]
𝐾𝑑 +[𝑀𝑒𝑡𝑁𝐼]

+ 𝐵𝑚𝑖𝑛

(Equation 8)

The fraction bound equation changed as well. This equation follows Equation 7 with the exception
that as MetNI increases, the fraction of bound MetQ decreases, resulting in Equation 9.

𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑜𝑢𝑛𝑑 = 1 −
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[𝑀𝑒𝑡𝑁𝐼]
𝐾𝑑 +[𝑀𝑒𝑡𝑁𝐼]

(Equation 9)

Chapter 3: Results

3.1: Protein Expression and Purification
In any biochemical project, significant quantities of protein must first be expressed and purified.
While the results below were mainly generated using published protocols (see references 1-5), the
complexity of the multi-day procedures warrant a detailed explanation and analysis, which is provided
below.12,3,4,5

3.1.1: MetNI Expression
The plasmids utilized for MetNI expression contained both the MetI and MetN genes, with a tenhistidine residue (10xHis) tag engineered at the N-terminus of the MetN. The 10xHis tag allowed for the
purification of MetNI protein via immobilized nickel affinity chromatography. To express MetNI, BL21
E. coli cells, known for their ability to express large amounts of exogenous proteins, were transformed with
plasmids via standard protocols. Large-scale growths in Terrific Broth (TB) media were induced with IPTG
(isopropyl β-D-1-thiogalactopyranoside) and harvested for subsequent purification.

3.1.2: MetNI Purification
Routine purifications starting
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Figure 3-1: Loading of protein supernatant onto a nickel affinity column.
Clarified cell lysate containing overexpressed MetNI was loaded onto a HisTrap
HP 5-mL column.

(DDM) was added to the MetNI buffer (50 mM[tris(hydroxymethyl)methylamino]propanesulfonic acid)
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(TAPS) pH 8.5, 250 mM NaCl, and 0.05% n-Dodecyl β-D-maltoside (DDM) to a final concentration of 1%

HisTrap nickel affinity column to purify
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protein was removed from the column in Figure 3-2: Washing and elution of MetNI protein from affinity column.
The dark trace indicates the absorbance at 280 nm, and the light trace

these wash steps, as seen in the spike in indicates the imidazole concentration.
absorbance that occurs when the elution

volume reaches ~90 mL in Fig. 3-2. Finally, MetNI was eluted from the resin using buffer containing 350
mM imidazole. The imidazole, present at high concentrations, competed with and displaced the 10xHis tag,
thereby promoting the elution of MetNI. Imidazole, when present at high concentrations (250 mM or
higher), outcompetes His-tagged protein for the nickel-resin beads, eluting the protein from the column.6
The resulting eluent (consisting mostly of MetNI) was injected onto a desalting column (HiPrep
26/10, GE Healthcare) to remove imidazole from the buffer. This step was crucial, as excess imidazole can
cause the protein to precipitate out of solution over time. Figure 3-3 plots the eluent’s conductivity and
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Superdex pg 200, GE Healthcare). In
Figure 3-3: Removal of imidazole from MetNI eluent. The collected

Figure 3-4, a small peak of aggregated eluent from the 5-mL HP HisTrap column was injected onto a HiPrep
26/10 desalting column. The dark trace depicts the absorbance at 280 nm

protein appeared at the void volume, while the light trace indicates conductivity.
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Figure 3-4: Size exclusion chromatography of MetNI. The collected
eluent from the desalting column was concentrated to 5 mL before injection
onto a HiLoad 16/600 Superdex pg 200 column.

solubilized proteins. Lane 5 is the flowthrough obtained from application of the supernatant over the HisTrap column. Lane 6 is the wash collected
using MetNI buffer containing 25 mM imidazole, and lane 7 is the wash collected using MetNI buffer
containing 75 mM imidazole. Lane 8 is the eluent collected when flowing buffer containing 350 mM
imidazole through the HisTrap column. Lane 9 is the eluent collected following injection of the HisTrap
eluent onto the HiPrep 26/10 desalting column. Lane 10 is the eluent following injection of the desalted
eluent onto the HiLoad 16/600 Superdex pg 200 size exclusion column.

Lane 1: Standard ladder
Lane 2: Cell lysate
Lane 3: Insoluble cell pellet
Lane 4: Solubilized cell
supernatant
Lane 5: His-Trap flow-through
Lane 6: 25 mM imidazole wash
Lane 7: 75 mM imidazole wash
Lane 8: 350 mM imidazole
eluent
Lane 9: Desalt chromatography
eluent
Lane 10: Sizing
chromatography eluent

Figure 3-5: SDS-PAGE analysis of the MetNI purification procedure.
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Outlined in blue boxes in Figure 3-5 are the dissociated MetN and the MetI portions of the
transporter. In lanes 3 and 4 (samples of cell pellet and cell lysate, respectively) the MetN and MetI bands
are enriched relative to other proteins, indicating a high level of expression. A considerable amount of
MetNI is found in the pellet following centrifugation (Lane 4), indicating that some protein remained in the
membrane. In lane 5 (HisTrap flow-through) the bands are noticeably lighter, indicating successful
retention of MetNI on the nickel resin. In subsequent purification steps, the MetN and MetI bands outlined
in red become more prominent, indicating a higher concentration of MetNI compared to contaminating
proteins. While the intensity of the transporter bands remains consistent across lanes 8-10, the presence of
contaminating proteins decreases as shown by the fading of the non-MetNI bands in each successive lane.
The final purified MetNI sample shown in lane 10 contains minimal amounts of contaminants and is
appropriate for use in subsequent assays.

3.1.3: MetQ Expression
The plasmids utilized for MetQ expression contained MetQ gene followed by a six-histidine residue
(6xHis) tag engineered at the C-terminus. The 6xHis tag allowed for the purification of MetQ protein via
immobilized nickel affinity chromatography. Similar to MetNI expression, BL21 E. coli cells were
transformed with plasmids via standard protocols.3
The protocol for large-scale expression of the MetQ substrate binding protein was modified to
increase yield. Previously, MetQ was expressed in autoinduction media, a method made popular due to its
ease of use.5 After numerous purification runs yielding low amounts of MetQ (1-3 mg per 18 g of cells),
MetQ expression was tested in TB media. SDS-PAGE analysis revealed a significant difference in
expression levels depending on growth media, as seen in Figure 3-6. Lane 1 is a molecular weight standard
ladder. Lane 2 contains cellular lysate from cells grown in autoinduction media, while lanes 3 and 4 contain
lysate from two separate growths using TB media. While less total cell lysate is loaded in lane 2, there is
an unambiguous increase in MetQ expression relative to other proteins in lanes 3 and 4. As a result of this
increased expression, subsequent purifications resulted in approximately 10-fold higher yield of MetQ, as
described below.
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Lane 1: Standard ladder
Lane 2: MetQ expressed in
autoinduction media
Lanes 3 & 4: MetQ expressed in TB
broth

Figure 3-6: SDS-PAGE of cell lysate from different cell growth protocols.
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Figure 3-7: Loading of periplasmic extract onto nickel affinity column.
Periplasmic extract containing overexpressed MetQ was loaded onto a 5mL HisTrap HP column.
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Figure 3-8: Washing and elution of MetQ protein from affinity column.
The dark trace indicates the absorbance at 280 nm and the light trace depicts
the imidazole concentration.

dimerization from occurring. To prevent artificial dimerization, the reducing agent beta-mercaptoethanol
(BME) was added to all buffers utilized in purification. Lastly, the periplasmic localization of MetQ
necessitated a significant modification to the purification protocol. MetQ is produced by ribosomes in the
cytoplasm of the cell. To target MetQ to the periplasm, a signal sequence on the nascent polypeptide chain
is recognized by specialized cellular machinery. MetQ is then shuttled to the inner membrane of the bacteria
and is eventually threaded through the membrane into the periplasmic space. Once inside the periplasm,
the signal sequence is cleaved from MetQ. The signal-sequence-containing MetQ and cleaved MetQ are
regarded as the immature and mature forms, respectively. As a consequence of over-expression, the
targeting and cleavage machinery of the cell can be overwhelmed, leading to increased amounts of

methionine, it was important to isolate

studies. To obtain mature MetQ, an
osmotic shock procedure was employed
to lyse only the outer membrane of the
E.coli cells, as described below.
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Figure 3-9: Removal of imidazole from MetQ eluent. The eluent collected
from the 5-mL HisTrap column was loaded onto a HiPrep 26/10 desalting
column. The dark trace indicates the absorbance at 280 nm, and the light trace
indicates the conductivity.
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membrane only. This was followed by the addition of Tris (50 mM final pH 7.5), sodium chloride (150 mM
final), and BME (5 mM final). Following osmotic shock, much of the MetQ purification procedure using
chromatography was similar to that of MetNI (Figs. 3-6 through 3-10). The osmotic shock solution was
centrifuged to separate non-periplasmic components from the periplasmic lysate (lanes 3 and 4). The
periplasmic lysate was loaded onto a HisTrap column, and the flow-through was collected (Fig. 3-7 and
Fig. 3-11, lane 5). Due to the lower affinity of 6xHis-MetQ for the nickel-resin beads, the multiple wash
steps used in MetNI purification were
omitted (Fig. 3-8).
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volumes. Based on the molecular Figure 3-10: Size-exclusion chromatography of MetQ. The eluent collected

from the desalt column was concentrated to 5 mL before injection onto a

weight of MetQ, the peak at 90 mL HiLoad 16/600 Superdex pg 200 column. The peak indicated by the blue

arrow is immature MetQ. The peak indicated by the red arrow is mature MetQ.

corresponds with a monomer of MetQ,
whereas the peak at 55 mL was unexpected. To investigate the composition of the peak at 55 mL, SDSPAGE was performed using samples from both peaks (Fig. 3-11). Lane 1 is a protein ladder, lane 2 is the
cellular preparation following osmotic shock, lane 3 is the cell pellet following centrifugation. Lane 4 is the
periplasmic extract, and Lane 5 is a sample of the flow-through from the 5-mL HisTrap HP column. Lane
6 is a sample of the following wash with MetQ buffer with 0 mM imidazole. Lane 7 is a sample of the
eluted protein collected when flowing MetQ buffer with 400 mM imidazole. Lane 8 contains sample that
overflowed from Lane 7. Lane 9 is a sample of the eluted protein following injection to the desalting
column. Lane 10 is a sample of the first peak (55 mL) eluted from the sizing column. Lane 11 is the second
peak (90 mL) eluted from the sizing column.
The conclusion from SDS-PAGE analysis was that the protein in the 55 mL peak was slightly larger
than the protein in the 90 mL MetQ (Fig. 3-11, blue and red arrows, respectively). One explanation for the
is that the 55 mL peak contained immature MetQ, which is slightly larger than mature MetQ due to its
uncleaved signal sequence. The hydrophobic nature of the signal sequence in immature MetQ may have
caused aggregation of this species, resulting in a distinct peak at 55 mL that is noticeably smaller than that
of the mature MetQ peak at 90 mL. This observation suggests that some of the inner membrane may have
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lysed despite the osmotic shock procedure. Eighteen g of BL21 cells gave a final sample of reasonable
purity and yielded 20-30 mg of purified MetQ protein.

Lane 1: Standard ladder
Lane 2: Cell lysate following
osmotic shock
Lane 3: Insoluble cell pellet
Lane 4: Solubilized periplasmic
extract
Lane 5: His-Trap flow-through
Lane 6: 0 mM imidazole wash
Lane 7: 400 mM imidazole eluent
Lane 8: Overflow from Lane 7
Lane 9: Desalt chromatography
eluent
Lane 10: Sizing chromatography
peak 1 (immature MetQ)
Lane 11: Sizing chromatography
peak 2 (mature MetQ)
Figure 3-11: SDS-PAGE analysis of MetQ purification procedure. The blue and red arrows identify immature and mature
MetQ, respectively.

3.2: Effect of Single Amino Acid Substitutions in MetNI
In this work, we utilized a well-established ATPase assay to verify the activity of wild-type
MetNI and to analyze the effect of single amino acid mutations in MetNI. This solution-based, real-time
assay is commonly utilized to accurately determine the ATP
hydrolysis rate of an enzyme. The protocol was modified to a
plate reader format, and 10-12 individual reaction conditions
could be tested simultaneously. Briefly, in this coupled
enzyme system, purine nucleoside phosphorylase (PNP)
catalyzes a reaction between inorganic phosphate and 2amino-6-mercapto-7-methyl purine riboside (MESG) (Fig. 312).7 A standard curve (see Fig 3-13) was generated by
measuring the amount of product, 2-amino-6-mercapto-7Figure 3-12: Schematic of the coupledenzyme reaction for the Enzchek Phosphate
Assay kit. Image taken directly from
ThermoFisher.6

methyl purine, which has a 1:1 ratio with inorganic phosphate
(reaction depicted in Fig. 3-12). 2-amino-6-mercapto-7methyl purine absorbs light at 360 nm, and thus the

absorbance at 360 nm is used as a measure of inorganic phosphate concentration, directly quantifying the
amount of ATP hydrolysis in a solution.
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Figure 3-13: Standard curve for conversion of absorbance to concentration of inorganic phosphate. The equation for the
best-fit line was y = 0.00195x + 0.2209 with an R2 value of 0.9956.

The raw data from a representative experiment is shown in Figure 3-14. In this particular assay,
the concentration of ATP was varied, and thus the absorbance at t = 0 varied between samples. ATP
hydrolysis requires the presence of Mg2+ ion, and a final concentration of 5.5 mM MgCl2 was injected into
each sample at t = 120 seconds to start the reaction. 27 To determine the rate of ATP hydrolysis, the time
points from 300-500 seconds were fit to a straight line. This time range provided the most reproducible
data, as earlier and later time points often showed non-linear trends or leveling off of the absorbance value,
respectively. The slope from the raw data was then converted into the observed rate constant (k obs) using
the conversion factor provided from the standard curve. Using this assay, the basic kinetic parameters,

Absorbance (AU)

→

including kcat, Km, and the Hill coefficient (n), were determined for MetNI.

Increasing
ATP
concentration

Figure 3-14: Raw data of MetNI ATPase assay with varying concentrations of ATP. Final concentrations of ATP varied from
0 – 5 mM ATP. A final concentration of 5.5 mM Mg 2+ was injected at time = 120 seconds, allowing ATP hydrolysis to begin.
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3.2.1 ATPase Activity of Wild-Type MetNI
First, to verify the quality of the protein resulting from the purification process, experiments using
wild-type MetNI with varying ATP concentrations were performed and compared to published data (Fig.
3-15). Data were fit to a modified Michaelis-Menten equation:

𝑘𝑜𝑏𝑠

𝑘𝑐𝑎𝑡 ∗ [𝐴𝑇𝑃]𝑛
=
𝐾𝑚 + [𝐴𝑇𝑃]𝑛

where kobs is the observed rate constant, kcat, is the catalytic rate constant, n is the Hill coefficient, and Km
is the Michaelis-Menten constant.

Figure 3-15: ATPase assay of wild-type MetNI in varying ATP concentrations. Best-fit parameters are kcat = 30 ± 3 min-1,
KmATP = 320 ± 120 μM , n = 0.9 ± 0.2.

As expected, ATP hydrolysis increased as a function of ATP concentration. The best-fit KmATP
value was 320 ± 120 µM, which is in good agreement with previously published work in which Km = 330
± 20 µM. In published work, experiments were performed at 33°C, while these assays were conducted at
37°C.8 This could explain the significant difference between the catalytic rate constant determined here, kcat
= 30 ± 3 min-1 and the published kcat value of 17 ± 1 min-1. Surprisingly, our results little cooperativity
based upon the Hill coefficient of 0.9 ± 0.2, while published data report that n = 1.7 ± 0.1. As a guiding
principle, a Hill coefficient of 0 signifies negative cooperativity between the two ATP binding sites, a
coefficient of 1 indicates no cooperativity, and a cooperativity of 2 signals positive cooperativity between
the binding sites. To confirm these preliminary results, further experimentation with lower concentrations
of ATP should be performed. Given the consistent values for kcat and Km, we concluded that the protein
purification process yielded MetNI with sufficient specific activity.
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Next, to verify the transinhibitory regulation of MetNI, ATPase activity was measured as a function
of L-methionine concentration. As expected, the hydrolysis rate decreased as concentrations of Lmethionine increased (Fig. 3-16). In this assay, at saturating concentrations of ATP, the ATPase activity
decreases and approaches zero. The Ki(L-Met) value was 41 ± 13 µM, in good agreement with previous
studies (41 ± 2 µM).7 This corresponds with the elegant in vivo observations from nearly 50 years ago,
which showed that high cellular concentrations of L-methionine inhibit further import. Thus, L-methionine
acts as both a substrate and inhibitor.

Figure 3-16: L-Met inhibits MetNI wild-type ATPase activity. Best fit parameters are Ki = 41 ± 13 μM, n = 1.2 ± 0.2, and
kcat = 28.5 ± 2.5 min-1.

3.2.2 Confirmation of the Loss of ATP Hydrolysis in MetNI E166Q Mutant
To trap an intermediate ATP-bound state of MetNI, a canonical single amino acid substitution was
employed. A glutamate to glutamine substitution in the Walker B motif of the NBDs allows the binding of
ATP but impairs hydrolysis. By eliminating the negative charge on the side chain, the residue no longer
acts as a general base, thereby reducing polarization of the water molecule involved in ATP hydrolysis.
Kadaba et. al. first introduced this mutant and demonstrated that E166Q MetNI was unable to hydrolyze
ATP.3 Similarly, our experiments showed a complete loss of activity for E166Q MetNI (Fig. 3-17, red).
These results, along with the crystallization of the E166Q transporter in the ATP-bound form, supports the
use of this mutant as a tool to examine the MetNI transporter trapped in its ATP-bound form.
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Figure 3-17: E166Q mutation eliminates MetNI ATPase activity. ATPase activity as a function of ATP concentration was
measured using ATPase assays of MetNI wild-type (black) and MetNI E166Q (red).

3.2.3 MetNI N295A Mutant
To generate a version of MetNI that cannot be inhibited, a previously described N295A mutant was
purified and tested.2 This mutant dramatically decreased the binding affinity between L-Met and the C2
domain using structural studies, however kinetic studies were absent. To ensure that the N295A mutation
solely affects transinhibition, but does not hinder ATP binding and hydrolysis, two ATPase assays were
conducted. First, we measured the ability of L-methionine to inhibit ATPase activity. As expected, the rate
of ATP hydrolysis by wild-type MetNI decreased as L-methionine concentrations increased (Fig. 3-18).
The Ki(L-Met) value of 41 ± 13 μM for wild-type MetNI was in agreement with the published data (Ki(LMet) = 41 ± 2 μM). In contrast, using the same series of L-methionine concentrations, the MetNI N295A

Figure 3-18: High L-Met concentrations do not inhibit MetNI N295A ATPase activity. ATPase activity as a function of LMet concentration was measured using MetNI wild-type (black) and MetNI N295A (red).
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mutant did not show any decrease in ATPase activity (Fig. 3-18, red). This data suggest that the N295A
mutation eliminates the transinhibition phenomenon of MetNI.
Next, the ATP concentration was varied to determine the kcat and KmATP of the mutant (Fig. 3-19).
The comparison of wild-type and N295A MetNI showed similar results, with kcat values of 30 ± 3 min-1 and
34 ± 4 min-1 , respectively. Additionally, KmATP values were within error, with values of 320 ± 120 µM
for wild-type and 365 ± 200 μM for N295A. These results demonstrate that the effect of the N295A
mutation is limited to the C2 regulatory domain and does not alter ATP binding and hydrolysis.
Together, the results from ATPase assays of wild-type, E166Q, and N295A versions of MetNI
establish that these mutations indeed serve their intended purpose. With this confirmation in hand, we
moved forward to determine the requirements for MetNI-Q complex formation.

Figure 3-19: N295A mutation does not alter MetNI ATPase activity. ATPase activities of MetNI N295A (red) and MetNI
wild-type (black) as a function of varying ATP concentration.

3.3 Development of Fluorescence Anisotropy Assay to Measure MetNI-MetQ Complex Formation
Fluorescence anisotropy is a widely accepted technique to measure the binding affinities between
biomolecules. The results from the assay give a broader range of Kd values than the frequently utilized
isothermal calorimetry (ITC) method.9 While surface plasmon resonance (SPR) has been successfully
employed to measure binding affinities between the BtuCD transporter and its cognate binding protein,
reliable results were not achievable with the MetNI transporter.10 The development of an anisotropy assay
to quantify the binding affinity of the MetNI-Q complex will be a valuable tool in establishing the
nucleotide and substrate requirements for association of the transporter and substrate binding protein. The
identification of intermediates in the reaction cycle will allow us to build a comprehensive model for
methionine transport.
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3.3.1: Labeling Substrate-Binding Protein MetQ with Fluorescein 5-Maleimide
In anisotropy experiments, one member of a binding interaction must be fluorescently labeled.
Ideally, the labeled protein alone and the protein complex are significantly different in size, with the smaller
protein being labeled. In this arrangement, the rotational lifetime of the labeled protein alone varies greatly
from that of the protein complex. For anisotropy experiments with the methionine transport system, the
substrate-binding protein MetQ (29 kD) was labeled. Given the 1:1 ratio of MetNI to MetQ per functional
transporter unit, the MetNI-MetQ complex has a molecular weight of 151 kD.
For these studies, activated fluorescein 5-maleimide dye was chosen because of its high quantum
yield (0.79), ideal fluorescence lifetime (~4 nanoseconds), and low anisotropy if the dye is unconjugated (r
= 0.021) versus attached to MetQ (r ~ 0.09).11,12 Fluorescein 5-maleimide was covalently conjugated via
maleimide chemistry to the single cysteine residue at amino acid position 23, near the N-terminus of MetQ.
This amino acid is not featured in the crystal structure of MetQ because it is unstructured, suggesting that
it is not critical for interaction between the two proteins.11
A brief summary of the MetQ labeling process is described here. More detailed procedures are
provided in the Methods section. First, the reducing agent in the buffer was exchanged from BME to TCEP,
as BME contains a thiol group that would react with the maleimide group on the dye. As recommended by
the manufacturer, fluorescein 5-maleimide was dissolved in DMSO to 100 mM final concentration. The
dissolved dye was added to a final concentration that was 5% DMSO (v/v) and 10-fold dye concentration
to that of MetQ (~50 µM MetQ). The mixture was incubated for two hours, and the labeling reaction was
quenched by addition of BME. The solution was then injected onto a 5-mL desalting column as a first step
in removing excess dye. To further wash the labeled MetQ, the protein was then added to nickel resin beads
in a standard 1.5-mL microcentrifuge tube. The 6xHis tag on MetQ allowed the capture of the labeled
protein on the nickel beads. The sample was centrifuged at 10,000 rpm for one minute, thereby separating
the beads and protein in the pellet and unconjugated dye in the supernatant. The supernatant was removed,
and fresh buffer was added to the beads. This batch wash procedure repeated three times or until a constant
absorbance at 492 nm was observed. The protein was eluted from the beads by addition of imidazole, and
imidazole was subsequently removed via buffer exchange. The absorbance at 280 nm and 492 nm was
measured for the samples (Table 3-1), which corresponds to the absorption maxima for protein and
fluorescein, respectively. This early labeling procedure was problematic and required significant
troubleshooting and optimization.
First, the amount of recovered protein following labeling was extremely low, with yields calculated
around 5%. Second, of the protein that was recovered, only ~3% of MetQ was labeled. Lastly, it was
suspected that a significant amount of unreacted dye remained in the final sample. The anisotropy value of
the labeled MetQ (r = 0.052) was not much higher than the recorded anisotropy value of the unconjugated
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maleimide dye (r = 0.032). This suspicion was raised after observing that latter batches of labeled MetQ
were measured to have anisotropy values near r = 0.09. It was important to remove as much unconjugated
dye as possible, as this contaminant would reduce the ability to detect changes in anisotropy.
Ideally, each potential issue would have been separately tested and analyzed to determine their
effect on labeling. However, to preserve time and resources, the labeling protocol was concurrently
modified in three ways. First, solid fluorescein dye was directly solubilized in MetQ buffer rather than
addition via a high concentration DMSO stock of the dye. This modification may be responsible for the
improved protein recovery (Table 3-1), as high concentrations of DMSO may have led to unfolding and
precipitation of protein. DMSO has been shown to trigger protein unfolding in concentrations as low as 4%
w/v.13 Second, the molar ratio of dye: protein was increased from 10:1 to 25:1. While expensive, the
investment in additional dye paid off, resulting in an ~33% increase in labeling (Table 3-1).
Lastly, to improve the efficiency of washing, the batch washing method was replaced with the use
of a gravity column. In a gravity washing method, nickel resin beads are packed into a gravity column. The
labeling reaction was added to the beads, and the protein was captured on this stationary phase. The beads
were then washed with a total of five mL of buffer instead of three mL administered in batch washing. This
gravity washing method effectively removed the unreacted dye, as suggested by the difference in anisotropy
values between the labeled MetQ produced from the batch method and the labeled MetQ from the modified
protocol (Table 3-3).

Table 3-1: Comparison of original and modified MetQ labeling protocols
Original Protocol
Abs 280 nm
Abs 492 nm

Modified Protocol
Abs 280 nm
Abs 492 nm

Flow-Thru

0.976

1.369

9.34

22.5

Wash #1

0.050

0.058

0.316

0.915

Wash #2

0.024

0.035

0.023

0.025

Wash #3

0.000

0.002

0.001

0.018

Eluent

0.000

0.179

3.157

4.406

Desalt

0.000

0.036

0.691

0.968

Final

% Labeling (Original Protocol)

% Labeling (Modified Protocol)

2.9%

35.7%

% Recovered

% Recovered

2%

20%
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Together, these modifications led to the reproducible labeling of MetQ with increased recovery and
labeling efficiency. Both protocols started with 6 mg of unlabeled protein, but the original protocol
recovered 1.7% of protein while the modified protocol resulted in 10-fold more recovery (17%).
Furthermore, the percent of MetQ that was labeled increased from 2.9% to 35.7%, as calculated using the
absorbance values at 280 nm and 492 nm and Equation 1 (see Methods). MetQ contains only one cysteine
amino acid, which ensures that a 1:1 ratio of protein: dye is the maximum that can be attained. In summary,
the optimization of the labeling protocol yielded suitable amounts of labeled MetQ for subsequent
anisotropy studies.
3.3.2: Anisotropy Control Measurements
As there was no recent precedent for anisotropy experiments at USF, a positive control was
developed to ensure proper operation of the in-house fluorimeter. First, solubilized dye was added to
varying concentrations of glycerol, and the anisotropy was measured. It was expected that increasing
amounts of glycerol, being much more viscous than water (1.412 Pa·s vs. 8.90 * 10-4 Pa·s, respectively),
would reduce the rotation of the dye, thereby increasing the anisotropy value. As predicted, the anisotropy
value increased as the percent volume of glycerol increased (Table 3-2). This trend provided initial
confidence in the procedure and in the settings employed on the Fluoromax (Horiba).

Table 3-2: Anisotropy values of solutions of fluorescein 5-maleimide in glycerol
% volume glycerol

Anisotropy

0

0.03160

5

0.04498

10

0.04641

20

0.05697

40

0.07413

60

0.11578

80

0.25341

To further assess the efficiency of the optimized protein labeling protocol, the anisotropy of free
fluorescein 5-maleimide dye was compared to that of labeled MetQ protein (Table 3-3). In this case, the
dye was resuspended in the same buffer as that of MetQ. The polarization value for labeled MetQ was
0.0902 ± 0.003, three times higher than the polarization value of free dye (r = 0.037 ± 0.004 ) and almost
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twice as high as the labeled MetQ produced from the initial batch protocol (r = 0.057 ± 0.003). These data
suggest that MetQ was successfully labeled during the labeling procedure and that minimal free dye remains
in solution.
Table 3-3: Comparison of anisotropy values of free fluorescein 5-maleimide dye versus maleimidelabeled MetQ.
Relative
Standard
Anisotropy
Deviation (%)
Unconjugated Dye
0.03681
10.5247
0.0567
6.0914
Labeled MetQ (Batch Protocol)
Labeled MetQ (Modified Protocol)

0.09019

3.6818

A series of preliminary experiments were conducted to determine the optimal experimental
conditions for measuring MetNI-Q interactions using a Fluoromax-4 Spectrofluorometer (Horiba). First,
the ideal concentration of labeled MetQ was determined through a series of serial dilutions.

Table 3-4: Concentration of fluorescein maleimide dye vs. average counts per second (CPS)
Concentration of fluorescein

Avg CPS @ 535 nm

maleimide dye (M)
1.00 ∗ 10-6

3.83 ∗106

5.00 ∗ 10-7

2.14 ∗106

2.00 ∗ 10-7

9.64 ∗105

1.00 ∗ 10-7

7.84 ∗105

2.00 ∗ 10-8

2.84 ∗105

1.00 ∗ 10-9

2.07∗105

The optimal zone for emission was between 1 x 105 to 2 x 106 counts per second (CPS) as per the
fluorometer user manual (Horiba). With MetQ labeled with at 20-30% on average, the optimal amount of
MetQ to use in each anisotropy trial was determined to be 20 nM. This concentration of MetQ was ideal,
as it produced sufficient signal for fluorescence anisotropy measurements while being far enough below
the anticipated Kd to provide maximal change in anisotropy.
Second, the buffer conditions from the ATPase assay did not interfere with fluorescence readings,
and thus the same conditions were used for anisotropy experiments. Lastly, the anisotropy was recorded
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over time with high concentrations of protein, to ensure that neither the buffer conditions nor the incubation
time required for equilibration resulted in aggregation.
3.4: Anisotropy Assays: Determining the Kd of the MetNI-Q Complex in Different Nucleotide and
Substrate Environments
3.4.1. Initial Anisotropy Assays using ATP
With successfully labeled MetQ and appropriate settings for the in-house fluorimeter, anisotropy
experiments to assess MetNI-Q complex binding affinities were ready to move forward. As a starting point,
the MetNI-Q complex formation was assessed in the ATP-bound state, as this was the conformation isolated
in crystallography studies.2,26 A double mutant E166Q/N295A MetNI was utilized. The E166Q mutation
prevented ATP hydrolysis, thereby allowing the trapping of ATP-bound states. As an extra precaution
against ATP hydrolysis, 3 mM EDTA was added in conjunction with 3 mM ATP to ensure removal of any
trace Mg2+ ions that would hydrolyze bound ATP. The N295A mutation hindered L-Met binding at the C2
domains, thereby eliminating any effect from transinhibition.
Using the in-house fluorimeter (Fluoromax-4 Spectrofluorometer), an experiment comparing the
binding affinities of L-Met bound MetQ (MetQ wild-type) and apo MetQ (MetQ N229A) with ATP-bound
MetNI was performed (Figure 3-20). The Kd value of apo MetQ with ATP-bound MetNI was determined
to be 83 nM after a single trial while the Kd value of L-Met bound MetQ with ATP-bound MetNI was
determined to be 2.7 µM. Previously published microscale thermophoresis studies found a similar trend
with apo MetQ having a higher binding affinity than wild-type MetQ.25
While these initial assays were a success, it became apparent that the labor and reagent requirements
of the experiment were unsustainable. A single experiment would take approximately 4-6 hours to

Figure 3-20: Initial anisotropy assays assessing MetNI-Q binding affinities in the presence of ATP. The black and red
curves are two separate assays performed with 20 nM MetQ N229A and MetQ wild-type, respectively.
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complete, as the in-house fluorimeter relied on a cuvette that holds only one 100 µl sample at a time.
Additionally, the concentration of MetNI necessary to saturate MetQ exceeded 10 µM, and at 100 µl per
sample, the total amount of MetNI was very substantial. Given the number of variables we planned to
examine, a more efficient method would be very beneficial, if not essential. For this reason, we explored
the possibility of using a spectrofluorimeter plate reader at UCSF. In this format, a single experiment could
be conducted in only 30-60 minutes and each well used only 20 µl. After weeks of troubleshooting the
procedure and equipment, anisotropy experiments were exclusively performed using a SpectraMax Gemini
XS Microplate Spectrofluorometer (Molecular Devices).
3.4.2: Complex Formation as a Function of MetNI Nucleotide State: Apo, ATP-Bound, and ADPBound
The first variable assessed was the nucleotide state of the MetNI transporter. During the reaction
cycle, possible nucleotide states include empty (or apo), ATP-bound, the ATP transition state, a posthydrolysis state, and ADP-bound. As a starting point, we chose to test three nucleotide states: apo, ADPbound, and ATP-bound. In structural studies, the MetNI-Q complex was crystallized in the ATP-bound
state, while MetNI alone was crystallized with ADP bound to its NBDs.2,26 While these structures provide
strong evidence of the nucleotide requirements for complex formation, the possibility of artifacts due to
crystal packing demands independent confirmation using a solution-based method. Discrepancy between
functional and structural studies have been debated regarding other ABC transporters. For example, the
original mechanisms for both the maltose (type I) and the vitamin B12 (type II) importers proposed based
on crystallography studies did not align with mechanisms proposed for the transporters based on functional
studies.13-1814,15,16,17,18,19

Figure 3-21: MetNI-Q complex formation requires ATP. Association of MetQ wild-type and MetNI E166Q/N295A was
measured in the presence of ATP/EDTA (black), ADP (blue), or no nucleotide (red).

51

To test the effect of MetNI nucleotide state on complex formation, the double mutant
E166Q/N295A MetNI was utilized, as described above. In these assays, 20 nM of wild-type MetQ was held
constant while the concentration of E166Q/N295A MetNI was varied from 0 - 20 µM. Either ATP and
EDTA, ADP, or no nucleotide was included in each reaction. While there was no detectable change in
anisotropy in either the ADP or apo state, a reproducible, robust change was measured in the presence of
ATP (Fig. 3-21). The data was best fit to a 1:1 binding curve with a Kd of 527 nM ± 107 nM. The formation
of the complex in the ATP-bound state is in agreement with previous crystallography studies,11 and is the
first measured Kd value for an ABC transporter using fluorescence anisotropy.

3.4.3 Role of MetQ Substrate-State in MetNI-Q Complex Formation: Apo (MetQ N229A) or L-Met
Bound (MetQ wild-type)
The second variable tested was the presence or absence of substrate bound to MetQ. In
crystallography studies, apo MetQ has been crystallized in complex with MetNI in its ATP-bound state,
however, attempts to capture an intermediate with substrate present were unsuccessful.2 This intermediate
has been trapped in both the maltose and molybdate transporters.20,21 We hypothesize, however, that Lmethionine must interact with MetQ at some point during the reaction cycle, as in vivo evidence suggests
that transport cannot occur if the MetQ gene is deleted.22 The same observation was made in both the
maltose and vitamin B12 transporters, where transport was not detected in the absence of the SBP in vivo
and in vitro, respectively.23,24
Due to its tight binding affinity, it is widely accepted that the substrate binding protein of ABC
transporters commonly co-purifies with its cognate substrate.25 To isolate substrate binding protein without
substrate (apo), a common technique is to unfold the protein in the presence of urea. Urea is a chaotrope
which disrupts the hydrogen bonding network of a solution or substrates. Following unfolding, MetQ is
refolded to its original shape via the slow removal of the chaotrope. To circumvent this time-consuming
and low-yielding process, Nguyen et al. introduced a single amino acid substitution (N238A) in Neisseria
meningitides MetQ that drastically increased the Kd nearly 400-fold (0.2 nM for wild-type to 78 µM for
mutant).26 Based on crystallography studies, this asparagine forms key hydrogen bonds with both the αamino and the α-carboxyl groups of the methionine substrate. By mutating this asparagine to alanine, a
mimic for apo MetQ was created, allowing for an alternative to the extensive unfolding-refolding process.
Apo MetQ could now be purified directly from cells overexpressing this mutant form of MetQ.
This strategy was implemented for use with E. coli MetQ. A mutation in the homologous site
(amino acid position 229) in E. coli allowed for the direct isolation of apoMetQ from E. coli cells. The use
of MetQ wild-type and MetQ N229A serves as equivalents for substrate-bound and apo MetQ, respectively.
The anisotropy assay described above was then performed using MetQ N229A. As with wild-type MetQ,
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no binding was detected for either ADP-bound or apo E166Q/N295A MetNI. Binding of MetQ N229A to
E166Q/N295A MetNI was observed in the presence of ATP, however the Kd was approximately 2-fold
lower than with wild-type MetQ (281 nM ± 36 nM vs 527 nM ± 107 nM, respectively) (Fig 3-22).

Table 3-5: Comparison of MetNI-Q complex binding affinities with substrate-bound MetQ vs. apo
MetQ

Kd

L-Met bound MetQ (wild-type) +

Apo MetQ (N229A mutant)

ATP-bound N295A MetNI

+ ATP-bound N295A MetNI

527 nM ± 107 nM

281 nM ± 36 nM

While apo MetQ (MetQ N229A) showed a two-fold higher affinity for ATP-bound MetNI than LMet bound MetQ (MetQ wild-type), this difference is relatively minor in a physiological setting. The
similarity in binding affinities suggests the possibility that both complexes may be involved in methionine
transport.

Figure 3-22: Binding affinity for ATP-bound MetNI. Complex formation was measured using MetNI E166Q/N295A
and MetQ N229A (red) and MetQ wild-type (black)

3.4.4: L-Met as an Inhibitor of MetNI-Q Complex Formation
The third variable assayed was the presence or absence of L-Met at the regulatory C2 domains.
Previous studies found that the ATPase activity of the MetNI transporter decreased with increasing
concentrations of L-Met, which is consistent with the transinhibition model first proposed by Kadner.27 In
crystallographic studies, MetNI containing L-Met bound to the C2 domains was trapped in its inward-facing
conformation, uncomplexed to MetQ.28 This transinhibitory mechanism has only been observed in the
methionine and molybdate transporters.29 However, the maltose and vitamin B12 transporters were captured
in an inward-facing conformation without their respective SBP.30 Furthermore, Chen et al. proposed that
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the maltose transporter in its IWF conformation complexed with its SBP (MalE) is an unstable, high energy
structure that quickly dissociated.31 While it is commonly accepted that binding of L-Met at the C2 domains
prevents association of the NBDs, it is unclear as to whether MetQ can bind MetNI in this inhibited state.
We hypothesize that transinhibition will sterically induce MetQ dissociation from MetNI.
To test if binding of L-Met to the C2 domains triggers the dissociation of the MetNI-Q complex,
the experimental procedure was designed to ensure that all MetQ molecules were in a complex with MetNI.
This experiment was performed by saturating 20 nM maleimide-labeled MetQ N229A with 1 µM MetNI
E166Q and 3 mM ATP/EDTA. These concentrations were informed by previous anisotropy experiments
(Section 3.4.2), where nearly 100% of MetQ N229A was in complex under these conditions. To ensure that
the total concentration of L-Met was controlled in each reaction, these anisotropy trials utilized apo MetQ
(MetQ N229A). This also ensured that L-Met was available to bind the C2 domains and not MetQ.
In a single preliminary trial, increasing concentrations of L-Met dissociated the MetNI E166Q MetQ N229A complex. The Kd for MetNI-Q complex dissociation by addition of L-Met was determined to
be 484 nM (Fig 3-23, see Methods for details of data fitting). Published ATPase measurements report a KI
of 41 ± 2 µM for L-Met to MetNI, which can be interpreted as synonymous to the Kd in this case. Though
the binding affinity measurement in this anisotropy assay differs from that of previous kinetic studies on
MetNI, this is the first evidence that L-Met binding to the C2 domain would inhibit MetQ association. Due
to COVID-19 pandemic, only one trial was completed for this experiment. Going forward in this project, it
will be crucial to repeat these experiments to determine the Kd. Experiments using higher concentrations of
L-Met will be important to obtain a reliable binding curve.

Figure 3-23: Preliminary anisotropy trial to determine Kd of L-Met - MetNI. Each reaction contained 20 nM MetQ
N229A, 1 μM MetNI E166Q, 3 mM ATP/EDTA, and varying concentrations of L-methionine. The Kd of L-methionine
to the C2 domain was 484 nM.
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Chapter 4: Discussion

This thesis addresses fundamental questions regarding the mechanism of the MetNI methionine
importer. Crucial technical advancements in this project include a modified protein purification protocol
with increased yield, an optimized MetQ labeling procedure, and the development of a reliable binding
affinity assay using fluorescence anisotropy. The techniques developed here and the resulting data have
allowed us to address key unknowns, such as the requirements necessary for MetNI - MetQ complex
formation and the details of the transinhibition phenomenon. This work not only presents insights into
MetNI transport but gives rise to further questions for both methionine import and ABC transporters in
general.

4.1: Optimization of MetQ Protein Purification and Fluorescent Labeling Protocols
One of the main limitations in many biochemical studies is the availability of pure protein.
Improvements in purification are a crucial first step necessary to ensure the feasibility of subsequent
experiments. Before optimization, MetQ expression and purification were inconsistent and yielded low
amounts of purified protein. The switch from autoinduction media to Terrific Broth media was a pivotal
discovery.
An excess amount of glucose in the autoinduction media may have led to the low protein yields. If
lactose is not completely digested then the lac operon would not be activated.1 Another explanation for the
low yield under these conditions is a decrease in O2 solubility at higher temperatures leading to less
breakdown of lactose and decreased protein expression.2 The use of Terrific Broth media, where protein
expression is induced by addition of a lactose analog, IPTG, produced a 5-fold increase in yield.
The second technical improvement was the optimized MetQ labeling procedure. Initial procedures
resulted in 1-2% protein labeling, which did not provide enough fluorescent signal for anisotropy assays.
Furthermore, the sample contained a high level of unconjugated dye, which masked changes in anisotropy.
Modified labeling methods, including altering the protein:dye ratio and buffer components, increased the
percentage of protein labeled. The use of a gravity column for washing efficiently removed unreacted
fluorescein 5-maleimide dye. Ultimately the modified labeling protocol saw 12 times more fluorescently
labeled MetQ, a crucial improvement for subsequent assays.

4.2 Development of Fluorescence Anisotropy Assay to Detect MetNI-Q Complex Formation
Previous attempts to measure the binding between MetNI and MetQ were difficult and unreliable.
Surface plasmon resonance (SPR) was successfully employed to measure binding for the BtuCD-F vitamin
B12 transporter however, adhesion of MetNI to the surface of the sensor chip was variable.3 Microscale
57

thermophoresis was used to gather evidence of MetNI binding to MetQ however, this technique is relatively
novel and is not commonly-accepted in the field.4 Isothermal titration calorimetry is a standard technique
to measure binding affinities that may be considered for measuring MetNI-Q binding, however, producing
the amount of purified protein necessary for these experiments would be exceptionally difficult for the
methionine transport system. Upon considering the challenges with the procedures mentioned, we
developed a new system to fully address questions regarding MetNI - Q complex formation.
Fluorescence anisotropy is a widely accepted technique to measure binding affinities. This method
measures solution-based equilibrium and requires standard instrumentation. Iterative experiments
determined the ideal conditions to measure the MetNI-Q interaction. Variables in the experiments included
the proper amounts of labeled MetQ for appropriate signal to noise ratios, ideal MetNI concentration ranges,
removal of aggregate protein, buffer conditions, and temperature. Preliminary experiments were conducted
using a standard cuvette-based fluorescence spectrophotometer. The protocol was subsequently adapted for
use in a 384-well plate reader format, which decreased the amount of purified protein required by 5-fold
per experiment. The modification to the plate reader format decreased the time required for each
experiment from six hours to only one hour of experimentation. The detailed procedure appears in the
appendix of this thesis for use in future projects.

4.3: ATP-Binding is a Prerequisite for MetNI-Q Complex Formation
One of the highly debated questions regarding ABC transporter mechanism is which nucleotide
state(s) promote(s) transporter-SBP complex formation. According to the anisotropy experiments we
performed, when MetNI was either nucleotide-free or trapped in an ADP-bound state, there was no
detectable change in anisotropy when added to labeled MetQ. These measurements were conducted with
both apo MetQ and L-Met-loaded MetQ. A lower bound for the Kd is approximately 20 μM, indicating that
the MetNI-Q complex does not form with MetNI in its nucleotide-free or ADP-bound states.
The Kd of ATP-bound MetNI with MetQ, whether it was apo MetQ or L-Met bound MetQ, was
much lower than results recovered with MetNI in the apo or ADP-bound nucleotide states (Kd values ranged
from 200- 600 nM), suggesting that ATP-binding by MetNI is a prerequisite for the MetNI-Q complex to
form. These findings are consistent with studies of the type I maltose importer in lipid nanodiscs and the
type II vitamin B12 transporter in detergent, which also reported ATP-binding as a prerequisite for
transporter-SBP complex formation.3,5 Additionally, crystallization of the MetNI-Q complex has only been
successful with the transporter in its ATP-bound state.6 This is likely the most common configuration of
the transporter as the normal ratio of intracellular ATP:ADP is 1000:1.7 With the anisotropy data mentioned
above, we conclude that MetNI requires ATP-binding as a prerequisite for MetNI-Q complex formation.
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4.3.1: The Presence of L-Met as a Substrate Does Not Significantly Alter Complex Formation
An unexpected discovery in this work, was the similar binding affinity between apo MetQ and
ATP-bound MetNI versus L-Met loaded MetQ and ATP-bound MetNI. The results from fluorescence
anisotropy experiments (Fig 3.14) in the presence of 3 mM ATP show that apo MetQ has a stronger affinity
for ATP-bound MetNI than L-Met loaded MetQ ((Kd = 281 ± 36 nM for MetQ N229A –MetNI
E166Q/N295A, Kd = 527 ± 107 nM for MetQ wild-type – MetNI E166Q/N295A), see Fig 3-22). Under
physiological conditions, this difference is not considered to be significant. While our results demonstrate
an approximate two-fold difference in affinity, previously published thermophoresis titration curves suggest
a 40-fold difference (Kd = 27 ± 9 nM for MetQ N229A – MetNI E166Q, Kd = 1100 ± 300 nM for MetQ
wild-type- MetNI E166Q).4 These previously published data were conducted under different in vitro
reaction conditions. Nguyen et. al completed the reaction in 1 mM ATP, 1 mM EDTA, 20 mM TAPS pH
8.5, 100 mM NaCl, and 0.3 % Cymal-5 while we performed our assays in 3 mM ATP, 3 mM EDTA, 0.06%
DDM, 150 mM NaCl, 57.5 mM Tris pH 7.5, and 10 mM TAPS pH 8.5. In addition, Nguyen et. al used a
novel technique, microscale thermophoresis, that has not been widely accepted by the scientific community
(personal communication with J. Yang). Further experimentation should be conducted to explore these
disparate results. The generation of meaningful binding curves validate the use of fluorescence anisotropy
to determine ABC transporter complex dissociation constants. Since fluorescence anisotropy can be adapted
to different protein complexes this advancement opens the door for future ABC transporter mechanism
research through the study of complex dissociation constants.

Figure 4-1: Visual representation of MetNIQ complex binding affinities. MetQ is shown in yellow, and L-Met is
represented by the maroon diamond. In the presence of 3 mM ATP, apo MetQ was found to have slightly higher affinity for
ATP-bound MetNI than L-Met bound MetQ. The Kd of MetQ N229A – MetNI N295A/E166Q is 281 ± 36 nM, and the Kd
of MetQ wild-type – MetNI N295A/E166Q is 527 ± 107 nM,

59

4.3.2: Evidence for Both Classical and Non-Canonical Mechanisms of Methionine Transport
The data presented in this thesis provide evidence in support of both the classical and noncanonical
models of methionine transport. In the classical model, MetQ first captures L-Met in the periplasmic space
and then shuttles the substrate to the membrane-bound transporter. Based on the results shown here, we
propose that ATP binding is a prerequisite for interaction between L-Met bound MetQ and MetNI.
Anisotropy data demonstrate that MetQ and MetNI do not interact in the absence of ATP, and thus the
“resting state” complex found in the maltose and vitamin B12 transporters may not exist for the methionine
transporter. Once substrate-loaded MetQ binds to MetNI in its OWF conformation, L-Met is released into
the transmembrane cavity, initiating ATP hydrolysis and triggering rearrangement to the IWF conformation
(Fig. 4-2).

Figure 4-2: A classical mechanism for methionine transport. When extracellular L-Met is present (red diamond), periplasmic
MetQ captures the substrate and delivers it to the transporter.

In the non-canonical model, apo MetQ binds to MetNI in its OWF, ATP-bound conformation. The
periplasmic substrate can then interact with the preformed complex, passing through MetQ to the
transmembrane cavity (Fig. 4-3). Our results show that apo MetQ interacts with MetNI only in the ATP
nucleotide state, and that neither ADP nor the apo nucleotide state support complex association.
The presence of two mechanisms may seem unnecessary for a transporter, however, some
researchers hypothesize each mechanism transports a unique substrate. Nguyen et al. proposed that the
preference for a particular mechanism may be triggered in response to environmental conditions. 8 When
extracellular L-Met concentrations are low, the cell can transition from importing L-Met via the classical
model to importing L-Met derivatives using the non-canonical model. They developed this hypothesis
upon depicting the structure of the MetNI-apo MetQ complex that had been solved by x-ray
crystallography. However, while this finding has opened the door to discovering a new mechanism,
crystallography studies place transporters in highly artificial environments and are best interpreted in
conjunction with functional studies. Our measurement of a relatively strong binding affinity for the apo
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Figure 4-3: A non-canonical mechanism for methionine transport. In this model, if L-Met is unavailable, MetQ will
dissociate from and rebind MetNI. A methionine derivative (red diamond) can access the translocation pathway if MetQ is bound
to the transporter. The substrate can then enter the transmembrane pathway and be transported across the membrane upon ATP
hydrolysis.

MetQ - MetNI complex strongly supports the existence of the non-canonical model. While MetQ N229A
has a higher affinity for ATP-bound MetNI (Kd = 281 nM + 36 nM), L-Met-bound MetQ was also able to
bind to MetNI with a reasonably strong affinity (Kd = 527 + 107 nM). The similarity in binding affinity
between L-Met bound and apo MetQ is a further indicator of the presence of the classical and non-canonical
mechanisms. Previous studies propose that there may be a substrate binding site in the translocation
pathway that is selective for the sulfur atom in L-Met derivatives8. This binding site would attract L-Met
derivatives to the MetNI-apo MetQ complex to initiate the non-canonical model. The possibility of a
substrate binding site in the transmembrane domains, combined with our functional data showing similar
binding affinities for both L-Met bound and apo MetQ - MetNI complexes, indicate that MetNI utilizes
both mechanisms for transport. Through these distinct pathways, the cell maintains sufficient amounts of
L-Met or L-Met precursors to maintain cellular function.

4.4: Transinhibition Mechanism of MetNI
In 1976, Kadner performed in vivo experiments in which the import of L-Met and D-Met decreased
as intracellular L-Met concentrations increased9. This transinhibition mechanism was observed when high
intracellular concentrations of methionine were present. This mechanism is thought to pause MetNI activity,
conserving ATP and preventing the import of a substrate that is already in excess. This process is activated
when intracellular L-Met binds to the C2 regulatory domains of MetNI, as based on both crystallography
and functional studies. Figure 4-4 depicts the proposed conformational changes that occur upon L-Met
binding to the C2 domains. Once L-Met binds to the C2 domains, the transporter is shifted to its inwardfacing conformation.8
To build upon this observation, we sought to provide solution-based evidence that L-Met binding
to the C2 domains can drive the dissociation of MetQ from MetNI. Using the fluorescence anisotropy assay
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developed here, the MetNI-Q complex appeared to dissociate upon addition of increasing concentrations
of L-Met. Using maleimide-labeled MetQ, the anisotropy value decreased when L-Met was added to a
preformed MetNI-Q complex, presumably due to L-Met binding at the C2 domains. By plotting the
anisotropy value as a function of L-Met concentration, the Kd value of L-Met to the C2 domains can be
determined. In a single preliminary anisotropy assay, the Kd of L-Met to the C2 domains was 484 nM (Fig.
3-15). The data comes from a single trial, and while more results are required to report a reliable Kd value,
this data provides a starting point in designing future assays. It will be crucial to perform this experiment
using the N295A mutation to test that this effect is due to binding at the C2 domains. Overall, this
preliminary result provides further detail to the transinhibition model (Fig. 4-4).

Figure 4-4: Binding of L-Met to the C2 domains of the transporter dissociates the MetNI-Q complex.

4.5: Future Experiments: Comparison of MetQ N229A and Apo MetQ Wild-Type
Given the tight affinity for L-Met, wild-type MetQ naturally co-purifies with L-Met expressed in
E. coli. To obtain apo MetQ, a laborious unfolding-refolding protocol has been developed (see Fig. 4-5).
The chaotrope guanidine hydrochloride is added to purified protein, disrupting the hydrogen bonds that
hold together a protein’s structure, triggering protein unfolding and the release of L-methionine. Guanidine
hydrochloride is then slowly removed, driving refolding of MetQ into an apo form. In this work, however,
we employed a mutant form of MetQ to reduce the time and resources necessary for experiments. This
mutant, N229A, was utilized in previously studies as a mimic for apo MetQ. While isothermal titration

Figure 4-5: The unfolding-refolding process of wild-type MetQ. Addition and slow removal of guanidine hydrochloride
removes the L-Met that co-purifies with wild-type MetQ.
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calorimetry experiments have shown that a similar mutation in Neisseria meningitides negates L-Met
binding, data regarding the E.coli MetQ N229A mutant is limited.10 Further evidence must be obtained to
confirm the use of this mutant as an appropriate substitute for apo wild-type MetQ.
The anisotropy assay developed in this work can be used to address this need. Specifically, the
binding affinities of unfolded-refolded apo wild-type MetQ for ATP-bound MetNI can be compared to that
of MetQ N229A. Similar Kd values would suggest that MetQ N229A binds to MetNI in a manner similar
to that of apo WT MetQ, and that this mutant is appropriate for future studies.

4.6: Chimeric MetNI Transporter to Study Role of Two ATPase Sites
Both structural and functional studies show similar outcomes that suggest the two NBDs of a single
transporter must come together during a reaction cycle. While there are two ATP-binding sites formed at
the interface of the NBDs, it remains unknown if both sites must bind and hydrolyze ATP. For example,
can MetNI function with a single bound ATP? Can MetNI function with two NBDs that bind ATP but only
one that is able to hydrolyze ATP?
To address these types of questions, future experiments will involve heterodimeric, or chimera,
transporters. In a chimera transporter, the TMDs would be identical but the NBDs would be different. Using
mutations in the NBDs, chimera transporters can be trapped in asymmetric nucleotide states. For example,
the mutant K44A involves a substitution in the Rec-A portion of the NBD. The loss of the lysine side chain
prevents binding of ATP in the active site. In contrast, the mutant E166Q allows the NBD to bind but not
hydrolyze ATP. Creating different pairings of wild-type, K44A, and E166Q mutations in the nucleotide
binding regions will provide insight into the mechanism of methionine transport. Clues as to the ATP
requirement for MetQ binding could be addressed using anisotropy assays. If there is no change in
anisotropy in experiments with rising heterodimeric MetNI concentrations in solutions of fluorescently
labeled MetQ, then that would reject the idea that that heterodimeric MetNI may successfully complex with
MetQ.
In order to generate MetNI chimeras, a different purification strategy must be employed. A pilot
protein purification using this strategy was successful, but was not pursued further due to time limitations.
To create a chimera, a His-tag is attached to one NBD with a specific mutation and a FLAG-tag is attached
to the other NBD with a different mutation. Since both mutations are expressed simultaneously in E. coli,
three different versions of transporters are produced. Specifically, the transporters have either two His-tags,
two FLAG-tags, or the chimera His-FLAG tags. To capture the desired chimera transporters, cell lysates
are purified using a Ni-NTA resin column followed by an anti-FLAG antibody column. Through this
tandem purification procedure, only chimera transporters with both the His-tag and the FLAG-tag would
be collected.
63

Next, assays will be carried out to ensure that chimera transporters show activity that are consistent
with that of homodimers. For example, His-FLAG chimeras which have two wild-type NBDs should show
the same ATPase activity as His wild-type homodimers. Similarly, His-FLAG chimeras which have two
E166Q NBDs should behave as did the His-E166Q homodimers measured in the anisotropy assays (Fig. 46). If Kd values and kinetic parameters for chimera transporters are comparable to those of homodimers,
then the project can move forward with evidence suggesting the addition of multiple tags will not interfere
with transporter activity.

Figure 4-6: Initial control assays using MetNI chimeras. MetNI transporters containing E166Q NBDs with different tags will
first be compared to singly-tagged E166Q NBDs. The binding affinities must be measured to ensure that any changes in
subsequent data are due to mutations in the ATP site and not an artifact of the tag.

4.7: Investigating the Number of ATP Required for MetNI-Q Complex Formation
Building upon our finding that ATP is required for MetNI-Q complex formation, the next question
is whether one or two ATP molecules are necessary for complex formation. Crystal structures of MetNI in
its ATP-bound state have shown two ATP molecules bound to the transporter NBDs.11 The ATPase activity
between the two NBDs exhibit positive cooperativity, meaning that the binding of one ATP molecule
increases the affinity for a second ATP molecule.12 This project aims to further understand ATP usage by
identifying the number of ATP molecules needed for complex formation. Anisotropy assays using chimeras
in which one nucleotide binding domain can bind but not hydrolyze ATP and another that is unable to bind
ATP would identify whether or not two functional ATP binding sites are required to form the MetNI-Q
complex. As briefly noted in Section 4.6, if there is no change in anisotropy in experiments with rising
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heterodimeric MetNI concentrations in solutions of fluorescently labeled MetQ, then that would reject the
idea that that heterodimeric MetNI may successfully complex with MetQ.
According to crystallography studies, MetNI in its apo nucleotide state resides in an inward-facing
conformation, which inhibits MetNI-Q complex formation. In the previously proposed model, the
transporter switches to its outward-facing conformation when two ATP molecules bind to the NBD region.8
The question that future work will address is whether one ATP binding at the NBD region provides
sufficient energy for the transporter to switch to an outward-facing conformation. In this outward-facing
conformation, it will be of great interest to determine if the transporter discriminates between apo and LMet bound MetQ (Fig. 4-7). Studies of other ABC transporters have shown different results when it comes
to the necessity of each ATP site. The type II importer BtuCD has been found to perform 5% of its maximum
transport with only one functioning ATP site.13 Previous studies have revealed positive cooperativity for
MetNI (n = 1.7), meaning that the two ATP binding sites cooperate with one another. Meanwhile, His
permease shows ~50% ATP hydrolysis activity with only one competent ATPase site.14 The type I maltose
transporter has also demonstrated positive cooperativity (n = 1.9 at pH 5), suggesting that two ATP binding
are necessary for a change in conformation.15

Figure 4-7: Investigation into the number of ATP required for MetNI-Q complex formation. The binding affinity between
MetQ and MetNI chimeras will be examined to see if binding of only one ATP to the NBDs affects the dissociation constant of
the MetNI-Q complex. The binding affinity of both apo MetQ (top) and L-Met bound MetQ (bottom) to MetNI chimeras
(pictured with one wild-type NBD (purple) and one degenerate NBD (salmon)) will be determined and compared to the binding
affinities of those complexes with two wild-type NBDs.
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In order to investigate the effects of one degenerate ATP binding site, a mimic for MetNI with
only one competent ATP-binding site must be purified. To mimic the binding of a single ATP molecule to
the NBD region, future research will focus on the purification and experimentation of MetNI chimeras with
one NBD that locks itself into the ATP-bound state (E166Q mutant) and one NBD that is unable to bind
ATP (K44A mutant). This chimera, named MetNI E166Q – K44A, will be able to bind only one ATP
molecule. Anisotropy assays of apo MetQ and L-Met bound MetQ will be performed with varying
concentrations of the MetNI E166Q – K44A chimera. The Kd will provide key insight into whether the
binding of only one ATP molecule is sufficient for MetNI-Q complex formation. If determined Kd values
for these MetNI (E166Q – K44A) – MetQ complexes are much higher than previously determined Kd values
(281 nM for the MetNI – apo MetQ complex and 527 nM for the MetNI – L-Met bound MetQ complex)
then there would be evidence to suggest the binding of two ATP is necessary for the MetNI-Q complex to
form.
A similar but distinct question about the MetNI transporter is whether or not one functioning
ATPase site is sufficient for ATP hydrolysis to occur in the NBD region. In other words, if two ATP can
bind to the NBDs but only one ATPase site can hydrolyze ATP, will the functioning ATPase site hydrolyze
ATP or does the transporter require two functioning ATPase sites for hydrolysis to occur? To examine this
question, a different MetNI chimera must be purified. This MetNI chimera must have one NBD that is able
to bind and hydrolyze ATP (wild-type) and one NBD that is able to bind but not hydrolyze ATP (E166Q
mutant). This MetNI chimera, named MetNI WT – E166Q will be utilized in ATPase assays to assess
whether or not one functional ATPase site is sufficient for ATP hydrolysis to occur. Furthermore, if ATP
hydrolysis can occur, it will be of interest to see if the rate of hydrolysis is similar or reduced in comparison
to that of wild-type MetNI.
A few of the possible outcomes of these experiments are depicted in Fig. 4.8. Shown in (A) is a
WT-E166Q MetNI chimera in which two ATP molecules are present and apo MetQ is in complex with the
transporter. If MetNI is capable of hydrolyzing only one ATP at a time, this could result in the transition
from (A) to (B), where apo MetQ remains bound to the OWF conformation of MetNI. In this case, the
energy from binding one ATP would be sufficient to hold together the NBD dimer, suggesting that
hydrolysis must occur at both ATP sites to drive transport. Alternatively, if the hydrolysis of one ATP may
destabilize the NBD dimer, shown as (A) to (C), the transporter could rearrange to the IWF conformation,
thereby driving dissociation of MetQ. This result would be consistent with a model in which only one ATP
is hydrolyzed during the transport cycle. In another scenario, shown in (D), MetNI may not be able to
hydrolyze any ATP, despite the fact that one NBD is functional. From this result, one could hypothesize
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Figure 4-8: Possible conformational changes to a MetNI-Q complex with a single active ATPase site. (a) With one wild-type
NBD (purple) and one E166Q mutant NBD (light pink), the transporter can bind two ATP molecules, triggering the outward-facing
conformation and allowing binding of MetQ. (b) One possibility is that the transporter can then hydrolyze only one ATP, and that
this may not be sufficient enough to drive rearrangement to the inward-facing conformation. (c) A similar but different possibility
is that the transporter hydrolyzes one ATP, and that this is sufficient to drive rearrangement to the inward-facing conformation. (d)
A third possibility is that both ATP sites must be functional in order for any hydrolysis to occur.

that two molecules of ATP are simultaneously hydrolyzed to trigger the switch from the OWF to the IWF
conformation.
The possibilities outlined above are a starting point for consideration, and this list of outcomes is
by no means comprehensive. The combination of ATPase and anisotropy assays developed in this thesis
will provide the tools necessary to dissect the role of the two ATP sites and their influence on complex
formation with MetQ. This would be a significant step forward to developing a complete understanding of
the MetNI transporter mechanism.

4.8: Lipid Environment of the Transporter: DDM vs. Nanodisc
All of the experiments performed with MetNI thus far have been conducted with the transporter
solubilized in the detergent n-dodecyl-β-D-maltoside (DDM). This detergent serves to extract the
transporter from the bilayer and to interact with the hydrophobic portions of the TMDs, thereby solubilizing
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the transporter. These experimental conditions are the most straightforward, as it only requires the addition
of detergent to buffers. All x-ray crystallography studies of MetNI have been solved in the presence of
detergent. However, MetNI may behave differently in a lipid bilayer in comparison to a detergent micelle.
For example, the maltose transporter has been observed to hydrolyze ATP in the absence of substrate and
SBP at a similar rate to when maltose and SBP are present, a phenomenon known as uncoupling. 16
Uncoupling of a transporter’s ATPase activity is not uncommon, especially with the protein in vitro. This
phenomenon is most prominent when the transporter is in lipid detergent. In the absence of maltose and
SBP, the maltose transporter recorded an ATPase activity of ~900 nmol/min/mg in detergent micelles. The
ATPase activity only slightly increases to ~1,000 nmol/min/mg (~11% increase) with maltose and SBP
both present in solution. With the transporter in lipid nanodisc, the ATPase activity increased from ~700
nmol/min/mg ~1500 nmol/min/mg (~110% increase) in the absence and presence of maltose and SBP,
respectively.16 Researchers from the Bao group observed that the lipid environment of a nanodisc places
more of a conformational constraint on the transporter, making the transporter more stable and less likely
to freely switch between the inward and outward facing conformations that hydrolyze ATP in the process.17
Due to the high level of uncoupled ATPase activity with transporter in detergent, many efforts have been
focused on the reconstitution of ABC transporters into lipid nanodiscs (Fig. 4-9).18
In light of these observations in related transporters, it will be important to measure MetNI-Q
complex formation using the transporter embedded in a nanodisc. These measurements will help to
determine whether the results observed in detergent faithfully replicate in vivo behavior. While ATPase
activity was mentioned to be affected by lipid activity, complex formation studied by Lewinson et. al. in
2010 found thermodynamic measurements for complex formation of the BtuCD-F transporter to be
similar whether the transporter was in proteoliposomes or in detergent.3

Figure 4-9: Lipid reconstitution of an ABC transporter. Reconstitution of MetNI into lipid nanodiscs may provide
additional insight into the mechanism of methionine transport. Figure inspired by (18).
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The results from assays performed in detergent will guide the following set of questions about
transporter mechanism, developing the assays, and introducing new experiments to examine how different
variables affect complex formation and transport mechanism.

4.9: Summary
This thesis presents multiple findings that reveal details of methionine transport. Through
adapting an anisotropy assay for an ABC transporter system, we show that ATP binding by MetNI is a
requirement for complex formation between the transporter and its periplasmic binding protein.
Anisotropy data suggests that MetNI has a slightly higher affinity for apo MetQ than L-Met bound MetQ,
an intriguing finding that suggests the further complexity of this transporter. Furthermore, we present
preliminary data that suggest that L-Met binding to the C2 regulatory domains of the transporter
dissociates the MetNI-Q complex, thereby preventing transport. Going forward, this project will continue
to uncover features of the MetNI mechanism. Yet to be discovered details include the number of ATP
molecules required per transport cycle and the intermediate states involved in transport of different
methionine derivatives. The elucidation of the MetNI mechanism will aid in understanding how ABC
transporters function in general, thereby enhancing our knowledge of related ABC transporters involved
in human diseases.
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Appendix
Detailed Instructions on Fluorescence Anisotropy Experiments
Materials
● 200 mM ATP (or close to)
● 10% DDM
● 2M or 5M NaCl
● 1M Tris
● Deionized H2O
● MetQ Buff A (150 mM NaCl, 25 mM Tris pH 7.5, 5 mM BME)
● MetNI Buff A (250 mM NaCl, 50 mM TAPS pH 8.5, 0.05% DDM)
● MetNI protein
● Labeled MetQ protein
● Ultracentrifuge tubes
● Laptop (for calculations and setup)
Procedure (Before UCSF)
● Email johnny.rodriguez@ucsf.edu and emily.wong3@ucsf.edu ahead of time to reserve the
ultracentrifuge and anisotropy plate reader
● Prepare buffers, ATP, EDTA, and DDM solutions a day before heading out to UCSF
Procedure (UCSF day) Preparing the proteins
● Turn on ultracentrifuge on 3rd floor, set to 4 C, 90,000 rpm. Get rotor and holder from cold room
● Turn on anisotropy plate reader (Agard Lab, 4th floor) so it can warm up for at least ~30 mins. Set the
temperature to 37 C.
A difficult part about this experiment is knowing how much protein to centrifuge at the beginning of
the day. Too many thawed aliquots and you waste precious protein, too little and you have to spend an
additional hour to prepare and use the ultracentrifuge and also prepare the correct concentration of MetNI
protein. To calculate the amount of protein needed it is crucial to predict the amount of non-aggregated
protein that will be present after centrifugation. Expect the protein concentration to decrease by 25% after
centrifugation. (For an estimate, 3 trials MetQ N229A – MetNI E166Q anisotropy assays required about
30 µL of 15 mg/mL MetNI and MetQ WT – MetNI E166Q assays required 90 µL of about 15 mg/mL
MetNI.
●

For each final concentration of MetNI in each trial, you need to make 5x concentrations for each. For
example, if one well needs a final MetNI concentration of 10 μM, then we need to make 50 μM
MetNI solutions. This is because the MetNI mix makes up 20% of the total volume of the final
sample volume. An example table can be seen below.
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Table 1: MetNI 5x serial dilution calculation. Concentration of stock MetNI was about 134 mM.
Final MetNI
MetNI
(nM)
MetNI 5x (nM)
Vol. previous (µL)
Buffer (µL)
10000
50000
18.63 stock
31.37
5000
25000
25.00 (50000 nM)
25.00
2500
12500
25.00
25.00
1000
5000
20.00
30.00
400
2000
20.00
30.00
200
1000
25.00
25.00
120
600
30.00
20.00
80
400
33.33
16.67
40
200
25.00
25.00
20
100
25.00
25.00
10
50
25.00
25.00
5
25
25.00
25.00
1
5
10.00
40.00
0.1
0.5
5.00
45.00
●

●

●
●
●

●
●

●
●
●

Add up all the stock MetNI needed and use it to predict the amount of MetNI protein needed. Keep in
mind, the bottom 20 µL of the centrifuged solution will be aggregated protein that will not be
collected, so add 20 µL to your predicted volume.
Pipette 20 µL of labeled MetQ (normally 20-30% labeled, curves may be noisier if less) and 80
µL MetQ Buff A into one centrifuge tube, find another tube and balance with 100 µL MetQ buff A.
(This should be more than enough labeled MetQ (assuming 1 mg/mL, only 20 nM for each well’s
final concentration).
Pipette the predicted necessary amount of stock MetNI into another centrifuge tube, balance with
another tube of equal volume MetNI buff A
Spin down in JLA-100 rotor for 20 minutes at 90k rpm
Once completed, change the temperature of the centrifuge to 25 C and close the centrifuge lid. This
helps with removing any condensation in the vacuum. Once the temperature reaches 25 C, open the
lid of the centrifuge and turn it off.
Pipette the centrifuged solutions into labeled eppendorf tubes. Leave 20 µL at the bottom of the tubes
to be certain that you do not pipette any of the aggregated protein.
Use the nanodrop located next to the fish tank to record Abs @ 280 nm and calculate concentrations
of each protein. Use the single readout option and perform the readings on sensor A1. Ext. coeff.
MetNI = 83365 M-1*cm-1, MW = 122034.85 g/mol ; Ext. Coeff. MetQ = 20400 M-1*cm-1, MW =
29431.65 g/mol
Adjust the MetNI well calculations according to the true concentration of the stock.
Create the 5x MetNI concentrations in labeled Eppendorf tubes and keep on ice.
Prepare the Master Mix solution
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Table 2: Anisotropy Master Mix Set-Up (60 reactions)

2M NaCl
1M Tris
10% DDM
100 mM
MgCl2
193 mM
ATP
ddH2O
66 nM MetQ
mix

MM (μL)
41.25
75
7.5
45
23.32
557.93
450

Total
1200
This table will give you 60 reactions worth of Master Mix with final well concentrations of 55
mM Tris pH 7.5, 5 mM TAPS pH 8.5, 0.055% DDM, 55 mM NaCl, 1 mM BME, 3 mM MgCl2, and 3
mM ATP. This table may change based on the variables of the experiment. Double check your
calculations before creating the master mix.
With the Master Mix and MetNI 5x solutions prepared, the procedure can begin. Make sure to
complete each step on ice until the solutions are transferred to the 384-black clear bottom (opaque bottom
may work too) well plate.
●
●
●
●
●

●
●
●
●
●
●
●
●
●
●

Label eppendorf tubes for rxn mixtures with their final MetNI concentrations
Pipette 20 µL of MM into each labeled eppendorf tube
Pipette 5 µL of MetNI 5x stock into their respective tube
Transfer 20 µL of each solution into their own respective well
Place the well plate in the plate reader and allow it to warm up for 10 minutes. To use the plate
reader, read the following instructions.
Press "Drawer" button on instrument, insert plate. Close "Drawer."
In Experiment window, check settings, Endpoint.
Read mode: Fluorescence or Fluorescence Polarity
Wavelength: default is 485 ex /538 em
Sensitivity: choose "High" unless signal is too Sat. "Precise" default setting is ok.
Assay Plate Type: 384 Grenier Blk/clr
Wells to Read: select
Press ok
Click on "Read" icon.
Save data under desktop > User > Laura > Janet. Taking a picture of the data is also a good idea.

Once all the assays have been performed, be sure to clean up your lab bench and turn off both the
ultracentrifuge and anisotropy plate reader. Sign up for the anisotropy plate reader on the calendar in the
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plate reader room if you know when you will return. If the next experiment day is unknown, email or text
Emily Wong afterwards to reserve a time to use the reader.
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